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1. Introduction 
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system 
(CNS). It is estimated that between 2 and 2.5 million people are affected by MS in the world and 
the disease is twice as common in women as in men (Milo and Kahana, 2010). MS is 
pathologically characterized by perivascular infiltrates of inflammatory cells, demyelination, and 
axonal damage, with the formation of multiple plaques in the brain and spinal cord. Clinically, 
MS patients show symptoms of visual disturbances, paresthesias, muscle weakness and ataxia. 
MS usually begins between the age of 20 and 50 and is the leading cause of disability resulting 
from CNS inflammation in young adults in western countries. So far, the cause of MS is still 
unclear, and not a single genetic or environmental factor has been unambiguously identified as 
the causative agent of MS. It is generally accepted that MS is a multifactorial disease caused by 
complex interactions between susceptibility genes and environmental factors. The leading 
environmental factor candidates are infectious agents, particularly Epstein-Barr virus (EBV), and 
vitamin D (Ascherio and Munger, 2007b; Ascherio and Munger, 2007a). 
Experimental autoimmune encephalomyelitis (EAE) is a widely used animal model to 
study MS. Both EAE and MS are inflammatory demyelinating diseases mediated by infiltration 
of T lymphocytes and macrophages in the CNS (McFarland and Martin, 2007; Baxter, 2007). 
EAE can be induced in mice by active immunization with myelin antigens such as myelin 
oligodendrocyte glycoprotein (MOG) peptide or passive transfer of myelin-reactive CD4
+
 T 
lymphocytes, which are both initiators and effectors of EAE.  Among CD4
+
 T cells,  T helper 1 
(Th1), T helper 17 (Th17), and granulocyte-macrophage colony-stimulating factor (GM-CSF)-
producing CD4+ T cells have been identified as important mediators in the immunopathogenesis 
of EAE and all of them can induce EAE independently (Lees et al., 2008; Stromnes et al., 2008; 
Codarri et al., 2011; Domingues et al., 2010). To some extent, T cell responses can be regulated 
by CNS-resident cells; therefore, some CNS-resident cell populations may play a critical role in 
the pathogenesis of MS and EAE. Neurons, though often neglected as immune-regulating cells, 
contribute to the suppression of EAE by controlling the conversion of encephalitogenic T cells to 
CD25
+
 Foxp3
+
 regulatory T cells (Liu et al., 2006). As active players in CNS innate immunity, 
astrocytes may play various roles in EAE. In our study, we are interested in elucidating the 
function of astrocyte-derived A20 and FasL in the pathogenesis and development of EAE. 
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1.1 Astrocytes 
 Astrocytes, also called astroglia, are star-shaped glial cells of the central nervous system (CNS) 
and are, therefore, named with the ancient Greek root word ‘astro’, which means star. Astrocytes 
are a major cellular constituent of the CNS. Astrocytes are characterized by their specific 
intermediate filament glial fibrillary acidic protein (GFAP) (Eng, 1985). Based on the 
morphology and location, rodent astrocytes can be classified into two distinct groups: highly 
ramified protoplasmic astrocytes in the grey matter, which ensheath synapses and blood vessels 
with their membraneous processes and fibrous astrocytes in the white matter, which are in 
contact with blood vessels and nodes of ranvier (Barres, 2008). Functionally, astrocytes provide 
an optimal physical and metabolic environment for neuronal activities. They play an important 
role in controlling potassium homeostasis in the extracellular space of the CNS. Active neurons 
release potassium, resulting in the local increase of extracellular potassium concentration. 
Astrocytes, which express potassium channels at a high density, rapidly clear potassium from the 
extracellular space (Walz, 2000). Upon stimulation by neurotransmitters, astrocytes produce 
neuroactive substances and trophic factors, thereby controlling development and function of 
synapses and neuronal survival. Purified retinal ganglion cells, a type of CNS neurons, cultured 
in the absence of astrocytes exhibit little synaptic activity although they express dendrites and 
axons and are electrically excitable. However, synaptic activity is strongly enhanced in retinal 
ganglion cells cocultured with astrocytes or cultured in culture medium conditioned by astrocytes 
(Pfrieger and Barres, 1997). Ullian et al. found that only few functionally immature synapses 
were formed between retinal ganglion cells cultured in the absence of astrocytes. Coculture with 
astrocytes strongly increases the number of synapses, and more importantly, astrocytes also 
enhance the presynaptic and postsynaptic functions of formed synapses (Ullian et al., 2001). 
Christopherson et al identified that astrocytes promoted CNS synaptogenesis by releasing 
thrombospondin (Christopherson et al., 2005). Thrombospondin is able to induce the formation 
of synapses that are ultrastructurally normal. In vivo, synapse number is significantly decreased 
in thrombospondin 1/2-deficient brains (Christopherson et al., 2005). In addition to promoting 
the formation and function of synapses, astrocytes also contribute to the survival of neurons. 
Astrocytes promote the growth and prolong the survival of neurons by producing neurotrophic 
factors (Banker, 1980). Neuronal survival is reduced in epidermal growth factor receptor 
(EGFR)-deficient mice, in which cortical astrocytes display increased apoptosis (Wagner et al., 
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2006). In addition to the important functions mentioned above, astrocytes also play important 
roles in CNS diseases. Astrocytes are activated during CNS diseases, leading to astrogliosis, 
which is usually beneficial because it helps to encapsulate infection and seal damaged blood 
brain barrier. In this regard, we have found that gp130-dependent astrocyte survival and 
astrogliosis are critical to restrict CNS inflammation in Toxoplasma encephalitis and EAE 
(Drogemuller et al., 2008; Haroon et al., 2011).  
1.1.1 Role of astrocytes in EAE  
According to the three stage theory of EAE (McFarland and Martin, 2007; Zepp et al., 2011), 
EAE includes (1) an initiation stage, in which myelin-reactive T cells are expanded in the 
periphery; (2) an effector stage, in which myelin-specific T cells are recruited to and reactivated 
in the CNS and start tissue destruction; and (3) a recovery stage, in which immune responses in 
the CNS are suppressed. Astrocytes are substantially involved in all three stages of EAE and play 
both beneficial and detrimental roles in this CNS autoimmune disease. 
Initiation stage 
In the initiation stage, astrocytes contribute to CNS immune privilege by forming the blood brain 
barrier (BBB), the location where first interaction between immune cells and CNS happens 
during neuroinflammation. The BBB is a composition of several different barriers that include 
tight junctions between CNS endothelial cells, low rates of endocytosis in endothelial cells, and 
high levels of export and import transporters (Zlokovic, 2008). The importance of astrocytes in 
the formation of BBB is presented by their ability to induce various BBB properties in 
endothelial cells of non-neural origin (Janzer and Raff, 1987; Kuchler-Bopp et al., 1999; Hayashi 
et al., 1997). In addition, the BBB-inducing function of astrocytes is conserved among species 
and rat astrocytes are able to induce neural endothelium-specific functions in human non-neural 
endothelial cells (Kuchler-Bopp et al., 1999; Hayashi et al., 1997). In addition to inducing other 
cells to form BBB, astrocytes themselves are also involved in the construction of BBB by 
building the glia limitans with their end-feet. As part of the BBB, astrocytes protect the CNS 
parenchyma from the invasion of encephalitogenic T cells in at least two ways: mechanical and 
functional. Due to specificities of glial basal lamina composition, the glia limitans is 
impermeable to T cells (Miljkovic et al., 2011; Bechmann et al., 2007). In order to migrate into 
the CNS parenchyma, T cells have to penetrate the glia limitans in cooperation with 
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macrophages/microglia (Tran et al., 1998). In addition to stopping T cells mechanically, 
astrocytes can also induce the apoptosis of T cells. The death ligand CD95L/FasL is 
constitutively expressed on the astrocytic end-feet and astrocytes can induce apoptosis of T cells 
in a FasL dependent way, thereby preventing the invasion of T cells into the CNS parenchyma 
(Bechmann et al., 1999; Bechmann et al., 2002). Although BBB is impermeable to most 
leukocytes, it can be crossed by low numbers of activated T cells that patrol the CNS. In the late 
phase of initiation stage, myelin-reactive T cells penetrate BBB nonspecifically and get 
reactivated by CNS antigens, leading to the effector stage. 
Effector stage 
The effector stage of EAE involves two waves of leukocyte invasion, which are associated with 
the initiation of EAE symptoms. After expansion in the periphery, myelin-specific T cells traffic 
through the choroid plexus to the subarachnoid space (Wave 1) where they are restimulated by 
antigens presented by menigeal APCs, including dendritic cells, macrophages and microglia 
(Engelhardt and Sorokin, 2009; Kebir et al., 2007; Reboldi et al., 2009). Since astrocytes can 
also express MHC class II, it is possible that astrocytes might also be able to present 
autoantigens to invading T cells in the CNS (Zeinstra et al., 2000). It has been shown that, during 
EAE, astrocytes can process and present MOG, proteolipid protein (PLP), and myelin basic 
protein (MBP) to encephalitogenic CD4
+
 T cells (Tan et al., 1998; Kort et al., 2006). 
As a result, T cells undergo clonal expansion and produce inflammatory cytokines, which 
stimulate adjacent CNS resident cells, in particular astrocytes, to produce leukocyte-recruiting 
chemokines and cytokines. Consequently, a large amount of perivascular leukocytes is recruited 
to the CNS parenchyma, leading to an explosive inflammatory cascade that is associated with the 
onset of EAE. At the effector stage, the large numbers of inflammatory cells, including T cells, 
migrate to the white matter of the CNS and initiate tissue destruction, including demyelination 
and axonal damage. As a major source of chemokines and cytokines in the CNS, astrocytes 
produce a large variety of chemokines and cytokines, including BAFF, GM-CSF, IFN-β, IL-1β, 
IL-6, TGF-β, TNF, CCL2, CCL5, CCL20, CXCL1, CXCL2, ,CXCL9, CXCL10, CXCL11, and 
CXCL12 (Brambilla et al., 2005; Kang et al., 2010; Zhou et al., 2011; Mason et al., 2001; 
Lieberman et al., 1989; Krumbholz et al., 2005; Diniz et al., 2012; Van Wagoner et al., 1999). 
Chemokines produced by astrocytes are of particular importance for the progression from Wave 
1 to Wave 2. The NF-κB signaling pathway, in synergy with MAPK and other signaling 
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pathways, plays a key role in modulating chemokine expression in astrocytes (Fig. 1). 
Inactivation of astroglial NF-κB significantly reduces CCL2 and CXCL10 expression in mouse 
ischemic injury (Dvoriantchikova et al., 2009). Ablation of NF-κB activators NEMO or IKK2 in 
astrocytes reduces the expression of proinflammatory chemokines including CCL5 and 
CXCL10, as well as the adhesion molecule VCAM1. As a result, CNS-restricted deletion of 
NEMO or IKK2 ameliorates EAE in mice (van et al., 2006). Consistently, Brambilla et al. also 
found that transgenic inactivation of NF-κB resulted in reduced disease severity and improved 
functional recovery during MOG35-55-induced EAE (Brambilla et al., 2009). Act1, an 
ubiquitinase capable of activating TRAF6 through K63-linked ubiquitination (Liu et al., 2009), is 
indispensable for the activation of the NF-κB cascade induced by IL-17 (Qian et al., 2007). In 
CNS-restricted Act1 knockout mice, IL-17 mediated NF-κB activation in astrocytes was 
abolished, leading to compromised production of chemokines, such as CXCL1, CXCL2 and 
CCL20, in the CNS and ameliorated EAE symptoms (Kang et al., 2010). TRAF3 is identified as 
a receptor proximal negative regulator of IL-17 receptor signaling and interferes with the 
formation of IL-17R-Act1-TRAF6 activation complex by competitive binding with the IL-17 
receptor. TRAF3 inhibits IL-17 induced NF-κB and mitogen-activated protein kinase activation 
and subsequent production of chemokines and cytokines. Similar to CNS-restricted ablation of 
Act1, over-expression of TRAF3 in the CNS can also ameliorate EAE (Zhu et al., 2010). 
Estradiol has been shown to inhibit NF-κB-dependent CCL2 expression in astrocytes in vitro. 
Consistently, in vivo, treatment with Estradiol decreases astrocytic CCL2 expression and 
ameliorates ongoing EAE (Giraud et al., 2010). However, not all the chemokines and cytokines 
produced by astrocytes during EAE are detrimental. In sharp contrast, CXCL12, which is 
upregulated in the CNS of MS patients, particularly produced by astrocytes, suppresses EAE by 
redirecting the polarization of Th1 cells into regulatory T cells (Meiron et al., 2008). In addition 
to producing T cell-manipulating cytokines and chemokines, astrocytes can also express iNOS, 
which produces NO and causes direct damage in the CNS. Blocking NO production by inhibition 
of iNOS reduces the severity of EAE (Zhao et al., 1996). Astrocytes are one of the most 
important sources of iNOS in the CNS during EAE (Tran et al., 1997) and their production of 
NO can be stimulated by fingerprint cytokines of encephalitogenic Th1 and Th17 cells, including 
IFN-γ , TNF, and IL-17 (Trajkovic et al., 2001; Saha and Pahan, 2006).  Demyelination is a 
major feature of EAE, and astrocytes contribute to demyelination through phagocytosis of 
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myelin (Lee et al., 1990) and production of molecules, such as redox reactants, that are toxic to 
oligodendrocytes (Antony et al., 2004).  
 
 
 
 
 
 
 
 
 
Figure 1. Signaling pathways induced by cytokines produced by encephalitic T cells 
T cells are effector cells of EAE and they produce various cytokines such as IL-1, TNF, IL-17, and IFN-γ. These 
cytokines activate multiple signaling pathways, including NF-κB, MAPKs, and STAT1, in astrocytes, leading to the 
production of various cytokines and chemokines, which are critical for the progression from wave 1 to wave 2 of T 
cell recruitment. 
Recovery stage 
The recovery stage, in which inflammation in the CNS is inhibited, is associated with elimination 
of invading leukocytes in the CNS and remyelination. Astrocytes contribute substantially to the 
recovery from EAE. After EAE onset, reactive astrogliosis is formed, in which astrocytes 
intensively proliferate and migrate to the lesions. Astrogliosis can be detrimental because the 
scar formed by astrocytes, characterized as a physical barrier around the demyelinated area, 
inhibits remyelination and neuro-regeneration (Bannerman et al., 2007; Nair et al., 2008). During 
EAE, astrogliosis and scar formation is absent in GFAP-TK transgenic mice, in which reactive 
and dividing astrocytes can be inducibly deleted (Voskuhl et al., 2009). However, due to the 
absence of scar-like perivascular barrier formed by astrocytes, inflammation and demyelination 
is more prominent and widespread in these mice, showing that astrogliosis is beneficial during 
EAE. We have shown that, during EAE, loss of gp130 expression results in apoptosis of 
astrocytes in inflammatory lesions of GFAP-Cre gp130
fl/fl
 mice, in which gp130 was specifically 
IKKγ 
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deleted in astrocytes. Due to astrocyte loss, GFAP-Cre gp130
fl/fl
 mice are unable to mount 
astrogliosis in EAE, leading to larger areas of demyelination and increased CD4
+
 T cell 
infiltration in the CNS (Haroon et al., 2011). Apoptotic elimination of encephalitogenic T cells in 
the CNS has been shown to be important for EAE resolution (Pender et al., 1991; Schmied et al., 
1993). Among CNS-resident cells, astrocytes may be key inducers of T cell apoptosis because 
(1) astrocytes express apoptosis-inducing FasL and autoreactive CD4
+
 T cells are Fas
+
 (Kohji 
and Matsumoto, 2000; Bonetti et al., 1997); (2) astrocytes are in intimate contact with apoptotic 
T cells during EAE (Kohji and Matsumoto, 2000); (3) astrocytes induce apoptosis of CD4+ T 
cells in vitro in a FasL dependent way (Bechmann et al., 2002). Therefore, astrocytes might 
contribute to EAE recovery by inducing apoptotic elimination of infiltrating autoreactive T cells. 
As a major source of cytokines, astrocytes can also promote EAE recovery by producing 
immunosuppressive cytokines, such as IL-27 (Hindinger et al., 2012; Fitzgerald et al., 2007). 
The costimulatory molecule cytotoxic T lymphocyte-associated antigen-4 (CTLA-4, CD152) 
provides inhibitory signals leading to inhibition of T cell activation and suppression of ongoing 
responses (Egen et al., 2002). Blocking CTLA-4 during the onset of EAE markedly exacerbates 
the diseases (Perrin et al., 1996). It was shown that astrocytes inhibited MBP-specific T cell 
activation, proliferation and effector function by enhancing CTLA-4 expression on T cells 
(Gimsa et al., 2004), indicating that astrocytes can also ameliorate EAE by inhibiting T cell 
responses. In sharp contrast to EAE-promoting Th1 and Th17 cells, regulatory T cells are 
protective in EAE. Astrocytes can also induce a regulatory phenotype among infiltrating 
autoreactive T cells, thereby mitigating the disease (Trajkovic et al., 2004). In addition, 
astrocytes can also contribute to EAE recovery by enhancing myelin repair. Astrocytes express 
matrix metalloproteinase 9 (MMP-9), which has been shown to mediate oligodendrocyte process 
growth (Uhm et al., 1998). MMP-9-deficient mice show impaired remyelination after a 
demyelinating insult (Larsen et al., 2003). MMP activity is inhibited by tissue inhibitors of 
metalloproteinases (TIMPs), which are also produced by astrocytes in demyelinating areas in 
EAE (Pagenstecher et al., 1998). Ablation of TIMP-1 in mice results in enhanced immune cell 
invasion and deficiency in myelin repair (Crocker et al., 2006).   
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1.2 Fas-FasL 
Fas, also called apoptosis antigen 1 (APO-1), cluster of differentiation 95 (CD95) or tumor 
necrosis factor receptor superfamily member 6 (TNFRSF6), is a death receptor on the cell 
surface that leads to apoptosis (Itoh et al., 1991). Mature Fas is a type I transmembrane protein of 
319 aa, consisting of a 157 aa extracellular domain and a 145 aa intracellular domain (Fig. 2). 
The extracellular domain contains three cysteine rich domains (CRDs), which are required for 
ligand binding (Orlinick et al., 1997). The intracellular domain contains a death domain, which is 
required for apoptosis induction (Itoh and Nagata, 1993). Expression of Fas has been detected on 
various cell populations, including cells of the hematopoietic system, epithelial cells, and 
fibroblasts. Fas ligand (FasL, also called APO-1L, CD95L, TNFSF6; CD178) is type II 
transmembrane protein that belongs to the tumor necrosis factor (TNF) family (Suda et al., 
1993). Structurally, FasL also consists of a 179 aa extracellular domain, which contains a TNF 
homology domain (THD) (Bodmer et al., 2002), and a 80 aa intracellular domain, which contains 
a proline rich domain (PRD). The receptor binding site (RB) is located at the very C terminus of 
FasL and mediates specific binding to the CRDs of Fas. FasL exists in two forms, either soluble 
or membrane-bound. Interestingly, only membrane-bound FasL triggers death induction, 
whereas soluble FasL counteracts it (O' Reilly et al., 2009). In fact, soluble FasL is 
chemoattractant and recruits neutrophils and phagocytes to the site of inflammation (Ottonello et 
al., 1999; Seino et al., 1998). 
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Figure 2. Domain structure of Fas and FasL 
Both Fas and FasL are transmembrane proteins, and consists of an extracellular domain and an intracellular domain, 
respectively. CRD, cysteine rich domain; RB, receptor binding site; THD, TNF homology domain; PRD, proline 
rich domain (modified from (Ehrenschwender and Wajant, 2009)) 
Binding of FasL with Fas induces the assembly of death inducing signaling complex 
(DISC). One crucial part of DISC is the receptor adaptor protein Fas-associated death domain 
protein (FADD), which bridges Fas with procaspase-8 (Chinnaiyan et al., 1995; Boldin et al., 
1996; Muzio et al., 1996) (Fig. 3). FADD directly binds to the death domain of Fas via its C-
terminal death domain and interact with procaspase-8 via its N-terminal death effector domain 
(DED), thereby mediating the recruitment of procaspase-8 to the DISC (Chinnaiyan et al., 1995; 
Boldin et al., 1995). Within the DISC, procaspase-8 is processed into mature heterotetrameric 
caspase-8 following its initial activation by dimerization, which is negatively regulated by 
FLICE-inhibitory protein (FLIP) (Wajant et al., 2003; Donepudi et al., 2003; Boatright et al., 
2003). Active caspase-8 is released from the DISC and induce the activation of effector caspases, 
in particular caspase-3, to mediate cell apoptosis. If caspase-8 levels are high, it directly activates 
effector caspases to trigger apoptosis (Maher et al., 2002; Peter and Krammer, 2003). However, 
in certain cells, caspase-8 expression is low. In these cells, caspase-8 cleaves Bid into tBid,  
which translocates to the outer mitochondrial membrane and activates Bak. Activated Bak 
oligomerizes and forms pores in the outer mitochondrial membrane allowing the release of 
proapoptotic proteins, including cytochrome c, to the cytoplasm (Barnhart et al., 2003). 
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Cytochrome c interacts with apoptotic protease-activating factor 1 (Apaf-1), ATP, and 
procaspase-9 to mediate capase-9 activation. Similar to caspase-8, active caspase-9 cleaves and 
activates caspase-3 to trigger the cell death machinery (Riedl and Salvesen, 2007). 
Expression of FasL is linked to the establishment of immunoprivilege and is essential for 
deletion of infiltrating inflammatory cells in immunoprivileged organs including the eye, brain, 
testicle and placenta (Griffith et al., 1995; Bellgrau et al., 1995; Hunt et al., 1997; Suvannavejh et 
al., 2000). Fas/FasL interaction is important for homeostasis of the immune system and its 
dysregulation leads to various autoimmune diseases. Naturally occurring mutant mice defective 
for Fas (lymphoproliferation, lpr) and FasL (generalized lymphoproliferative disease, gld) 
develop lymphadenopathy and suffer from an autoimmune syndrome similar to human systemic 
lupus erythematosus (Takahashi et al., 1994; Watanabe-Fukunaga et al., 1992). FasL knockout 
mice exhibit a severe autoimmune phenotype with splenomegaly and lymphadenopathy and die 
early after birth (Karray et al., 2004). 
Fas and FasL are also involved in the pathogenesis of EAE, as EAE symptoms are 
ameliorated in lpr and gld mice in terms of disease incidence and mean clinical score (Waldner 
et al., 1997). Apoptosis of oligodendrocytes mediated by Fas/FasL plays a central role in EAE. 
Selective ablation of Fas or FADD in oligodendrocytes ameliorates EAE (Mc et al., 2010; 
Hovelmeyer et al., 2005). In addition, elimination of infiltrating T cells in the CNS by apoptosis 
is crucial for resolution of EAE (Schmied et al., 1993; Pender et al., 1991). Intrathecal infusion 
of recombinant FasL induces apoptosis of CNS-infiltrating inflammatory cells, including T cells 
and macrophages, but does not exert cytotoxicity against CNS-resident cells, resulting in 
mitigated EAE manifestations (Zhu et al., 2002). FasL-deficient gld recipients develop prolonged 
EAE after adoptive transfer of myelin basic protein (MBP)-reactive wild-type Fas+ T 
lymphocytes, indicating that Fas/FasL-mediated apoptotic elimination of T cells from the CNS is 
important for EAE recovery (Sabelko-Downes et al., 1999). However, the CNS-resident cell 
population which induces apoptosis of CD4
+
 T cells in EAE still remains to be identified. We 
hypothesise that astrocytes, which constitutively express FasL, may play a key role given that 
FasL-expressing astrocytes are in intimate contact with apoptotic T cells in EAE and can induce 
apoptosis of activated CD4
+
 T cells in vitro (Bechmann et al., 2002; Kohji and Matsumoto, 
2000). 
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Figure 3. Fas mediated apoptosis-inducing pathway 
Upon binding with FasL, Fas activates proapoptotic signaling pathways. In cells with affluent caspase 8, effector 
caspases, including caspase 3, is activated directly by caspase 8. In cells where caspase-8 expression is low, caspase-
8 truncates Bid to produce tBid, which further activate Bak. Cytochrome c is released from Bak pores formed in the 
outer mitochondrial membrane and activate caspase-9, which further activates caspase-3. DD, death domain; DED, 
death effector domain 
1.3 NF-κB pathway 
NF-κB is a family of transcription factors that regulates various biological functions, including 
immune response, cell differentiation, proliferation and survival (Hayden and Ghosh, 2008; 
Vallabhapurapu and Karin, 2009). Upon bacterial and viral infection, stimulation with 
inflammatory cytokines, and activation of antigen receptors, NF-κB transcription factors regulate 
gene transcription by binding as dimers to κB enhancers or promoters. In mammals, the NF-κB 
family is composed of five members: RelA (p65), RelB, c-Rel, NF-κB1 p50 (processed from 
precursor protein NF-κB1 p105), and NF-κB2 p52 (processed from precursor protein NF-κB2 
p100) (Oeckinghaus et al., 2011) (Fig. 4). All NF-κB proteins share a conserved Rel homology 
domain (RHD), which is required for dimerization, DNA binding, IκB interaction, and nuclear 
translocation (Ghosh et al., 1998). Based on their transactivation potential, NF-κB transcription 
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factors can be further divided into two groups because only RelA, RelB, and c-Rel have a 
transactivation domain (TAD). p50 and p52 do not have the TAD and they positively regulate 
transcription by interacting with RelA, RelB, c-Rel, or other co-activators (Hayden and Ghosh, 
2011). Overall, two main NF-κB pathways exist in cells, i.e., the canonical NF-κB pathway and 
the noncanonical NF-κB pathway. 
 
 
 
 
 
 
Figure 4. NF-κB members 
Structure of the NF-κB family members. ANK, ankyrin-repeat; DD, death domain; GRR, glycine-rich region; RHD, 
Rel homology domain; TAD, transactivation domain. 
1.3.1 The canonical NF-κB pathway 
The canonical NF-κB pathway is dependent on NF-κB transcription factors RelA and p50. In 
resting cells, RelA and p50 dimers are sequestered in the cytoplasm by inhibitory IκB proteins. 
The canonical pathway is activated in response to activation of specific cytokine receptors, 
antigen receptors, and pattern-recognition receptors (Fig. 5). Upon NF-κB activation, IκB is 
phosphorylated by the trimeric IκB kinase (IKK) complex, which comprises two catalytically 
active kinases, IKKα and IKKβ, and the regulatory/scaffold subunit IKKγ (NEMO) (Karin and 
Ben-Neriah, 2000). Phosphorylated IκB is subsequently K48-ubiquitinated and degraded by 26S 
proteasome. As a result, the RelA/p50 dime is free to translocate to the nucleus to initiate the 
transcription of target genes. It is of note that ubiquitination is important for regulating canonical 
NF-κB activation and key signaling molecules, including TRAF6, IRAK1, RIP1, IκB, and 
NEMO, are all targets of ubiquitination (Wertz and Dixit, 2010). 
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1.3.2 The non-canonical NF-κB pathway 
A subset of TNF superfamily ligands, such as BAFF, lymphotoxin, LIGHT, CD40L, RANKL, 
and TWEAK, activate the non-canonical NF-κB pathway (Claudio et al., 2002; Coope et al., 
2002; Dejardin et al., 2002; Novack et al., 2003; Wicovsky et al., 2009) (Fig. 5). The non-
canonical NF-κB pathway regulates various biological activities, including lymphoid organ 
development, B cell survival and activation, dendritic cell activation, and osteoclastogenesis 
(Dejardin, 2006; Sun, 2011). Upon non-canonical NF-κB activation, NIK is stabilized and 
phosphorylates IKKα. Phosphorylated IKKα homodimer induces the processing of p100, which 
forms a dimer with RelB. The p100/RelB dimer is sequestered in the cytoplasm because p100 
functions as an IκB-like molecule and inhibits RelB nuclear translocation (Solan et al., 2002). In 
an ubiquitination-dependent way, p100 is processed to p52. The newly generated RelB/p52 
complex then translocates to the nucleus to start gene transcription. Stabilization of NIK is 
essential for non-canonical NF-κB activation. In resting cells, the level of NIK is extremely low 
because it is constantly ubiquitinated by cIAP, which leads to its proteasomal degradation 
(Zarnegar et al., 2008).  
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Figure 5. The NF-κB pathway 
The canonical NF-κB pathway is dependent on activation of IKKα, IKKβ, and IKKγ. Activation of the trimeric IKK 
complex leads to the phosphorylation of IκBα, which is further K48-ubiquitinated and subsequently degraded by the 
26S proteasome. The RelA/p50 dimer is then free to translocate to the nucleus and initiates transcription. Activation 
of the noncanonical NF-κB is NIK-dependent. Accumulation and activation of NIK causes the activation of IKKα. 
Activated IKKα induces the processing of p100 to p52. The RelB/p52 dimer then translocate to the nucleus to start 
gene transcription. 
1.4 Ubiquitination/ Deubiquitination 
Ubiquitin, an 8.6 KD protein consisting of 76 amino acids, is highly conserved among eukaryotic 
species. Ubiquitination is an important post-translational modification and catalyzed by a 
cascade of three different kinds of enzymes: ubiquitin-activating enzymes (E1s), ubiquitin-
conjugating enzymes (E2s), and ubiquitin-ligases (E3s) (Fig. 6). Utilizing ATP, E1s generate a 
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thioester bond between the carboxyl terminus of ubiquitin and the E1 cysteine sulfhydryl group 
(Schulman and Harper, 2009). The activated ubiquitin is then transferred to the cysteine in the 
active site of an E2. Ubiquitin is finally transferred to a target protein catalyzed by an E3, which 
interacts with both the E2 and the target protein. So far, 2 E1s (UBA1 and UBA6), 38 E2s, and at 
least 600 E3s have been discovered in human (Deshaies and Joazeiro, 2009). 
 
 
 
 
 
 
 
 
 
 
Figure 6. Ubiquitination process 
The ubiquitination process involves a cascade of three enzymes. Ubiquitin-activating enzymes (E1s) activate 
ubiquitin. Ubiquitin-conjugating enzymes (E2s) transfer ubiquitin to ubiquitin ligases (E3s). E3s attach ubiquitin to 
substrates. The elongation of polyubiquitin chains is mediated by both E2s and E3s. 
Ubiquitination was initially characterized as a mechanism to trigger proteasomal 
degradation of target proteins. However, ubiquitination is also involved in other cellular 
functions, including membrane trafficking, endocytosis, and, in particular, signal transduction. 
The functions of ubiquitination are decided by the patterns of ubiquitin linkage to target proteins. 
Ubiquitination of a substrate may be mediated by a single ubiquitin molecule 
(monoubiquitination) or a chain of covalently linked polyubiquitin molecules 
(polyubiquitination) (Fig. 7). Monoubiquitination and multi-monoubiquitinations are important 
for membrane trafficking, endocytosis, and viral budding (Miranda and Sorkin, 2007; Ikeda and 
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Dikic, 2008). Polyubiquitination is mediated by seven internal Lys residues, i.e., K6, K11, K27, 
K29, K33, K48, and K63. A mass spectrometry analysis has shown that K6-, K11-, K27- , K29, 
and K48-linked ubiquitin chains can all mediate proteasomal degradation (Dammer et al., 2011). 
Indeed, K48-linked ubiquitination has been well characterized as a mechanism inducing 
degradation of target proteins by 26S proteasome (Hershko and Ciechanover, 1998). In addition, 
K11-linked ubiquitin chains are characterized as degradative signals in cell cycle regulation (Jin 
et al., 2008; Kirkpatrick et al., 2006; Matsumoto et al., 2010). In sharp contrast, K63-linked 
polyubiquitin chain regulates non-degradative activities such as signal transduction (Adhikari et 
al., 2007; Hershko and Ciechanover, 1998). 
 
 
 
  
 
 
Figure 7. Forms of ubiquitination 
There are three forms of ubiquitination: monoubiquitination, multi-monoubiquitination, and polyubiquitination. 
Polyubiquitination chains are linked by K6, K11, K27, K29, K33, K48, and K63 residues, respectively. 
Ubiquitination is reversible and can be counter-regulated by a family of deubiquitinating 
enzymes (deubiquitinases, DUBs). The human genome encodes nearly 100 DUBs, which can be 
classified into 5 distinct subfamilies based on structural domains: ubiquitin-specific proteases 
(USPs), ubiquitin C-terminal hydrolases (UCHs), ovarian tumour proteases (OTUs), Josephins, 
and JAB1/MPN/MOV34 metalloenzymes (JAMMs, also known as MPN
+
) (Skaug et al., 2009; 
Reyes-Turcu et al., 2009). USPs, UCHs, OTUs, and Josephins are cysteine proteases, whereas 
JAMMs/ MPN
+
 are zinc
2+
 metalloproteases. The largest subfamily of DUBs is the USP 
subfamily, which consists of more than 50 members including Cylindromatosis (CYLD) (Sun, 
2010; Sun, 2008). The OTU subfamily is the second largest, comprising many important NF-κB 
regulators such as A20, Cezanne (OTUD7B), and Otubain-1 (Enesa et al., 2008; Hu et al., 2013; 
Li et al., 2010). 
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1.5 Regulation of immune responses by A20 
A20, also known as tumor necrosis factor alpha-induced protein 3 (TNFAIP3), was originally 
identified as a TNF-inducible gene in human umbilical vein endothelial cells (HUVECs) 
(Opipari, Jr. et al., 1990). In many cell types, expression of A20 is kept at low levels but can be 
rapidly enhanced by proinflammatory cytokines or mitogens. In contrast, thymocytes and T cells 
express relatively high levels of A20 and A20 expression in these cells can be downregulated 
upon stimulation with T cell receptor agonists (Tewari et al., 1995). As a zinc finger protein, A20 
has seven zinc finger domains (C2H2) in the C-terminus and an ovarian tumor (OTU) domain, 
which exerts the deubiquitinase activity, in the N-terminus (Evans et al., 2004; Wertz et al., 
2004) (Fig. 8). Initially, A20 was found to play a pro-survival role in protecting cells from TNF-
induced cytotoxicity (Opipari, Jr. et al., 1992), and subsequent studies gradually revealed its 
function as a negative regulator of the NF-κB signaling pathway induced by various stimuli, 
such as IL-1, TNF, CD40, and PRRs (Jaattela et al., 1996; Lee et al., 2000; Beyaert et al., 2000). 
Both findings were further confirmed by studying A20-deficient (Tnfaip3-/-) mice (Lee et al., 
2000). Tnfaip3
-/-
 mice are hypersensitive to proinflammatory stimuli, including TNF and LPS, 
and die prematurely due to unfettered multi-organ inflammation and cathexia. Activation of NF-
κB induced by TNF and IL-1 persisted in A20-deficient mouse embryonic fibroblasts (MEFs) as 
indicated by prolonged IKK activation and IκBα degradation. In addition, its anti-apoptotic 
function was also confirmed by showing that A20-deficient MEFs were sensitive to TNF-
induced programmed cell death (Lee et al., 2000). In addition to its well studied role in 
restricting the canonical NF-κB signaling, A20 has been shown to regulate other signaling 
pathways, such as non-canonical NF-κB signaling, interferon regulatory factor (IRF) pathway 
and Wnt pathway (Yamaguchi et al., 2013; Saitoh et al., 2005; Shao et al., 2013). 
Mechanistically, A20 is an ubiquitin-modifying enzyme. A20 cleaves K63-linked polyubiquitin 
chains via its DUB activity and can also build K48-linked polyubiquitin chains through its E3 
activity. 
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Figure 8. Domain structure of A20 
In the N-terminus of A20, there is an OTU domain that is responsible for the DUB activity of A20. There are 7 zinc 
finger domains (ZnF) in the C-terminus of A20. ZnF4 confers A20 E3 ligase activity. ZnF6 and ZnF7 are involved 
in lysosomal targeting. 
1.5.1 Function of A20 in apoptosis 
A20 has both pro- and anti-apoptotic functions. Initially, A20 was found to be anti-apoptotic 
(Opipari, Jr. et al., 1992). Indeed, A20 functions as an anti-apoptotic protein in many cell types. 
A20 protects endothelial cells from TNF- and Fas-induced apoptosis by inhibiting caspase 8 
activation (Daniel et al., 2004). Activation of the TNF-related apoptosis-inducing ligand 
(TRAIL) death receptor induces ubiquitination of caspase-8 by a cullin-3 (CUL3)-based E3 
ligase (Jin et al., 2009). Overexpression of CUL3 increases ubiquitination and activity of 
caspase-8. Interestingly, A20 was found to be part of the DISC and physically interact with 
caspase-8. Overexpression of A20 reverses CUL3-mediated polyubiquitination of caspase-8 and 
inhibits caspase-8 activity, indicating that A20 excerts its anti-apoptotic function through 
deubiquitination and inhibition of caspase-8 (Jin et al., 2009). In the DISC induced by TRAIL, 
the C-terminal ZnF domain of A20 mediates polyubiquitination of RIP1 through K63-linked 
polyubiquitin chains. RIP1 and K63-linked polyubiquitin chains bind to the protease domain of 
caspase-8 and inhibit its dimerization and cleavage, resulting in inhibition of TRAIL-induced 
apoptosis (Bellail et al., 2012). Upon TNF stimulation, A20 binds to apoptosis signal-regulating 
kinase-1 (ASK1), an important upstream kinase in the JNK signaling pathway, and promotes its 
degradation through K48 ubiquitination, leading to inhibition of JNK signaling and eventually 
blockage of apoptosis (Won et al., 2010). In addition, overexpression of A20 protects islets of 
Langerhans from apoptosis induced by IL-1β and IFN-γ, and this is dependent on its inhibitory 
function in cytokine-induced NO production (Grey et al., 1999). 
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However, in several cell types, A20 plays a pro-apoptotic role. In the absence of A20, 
bone marrow-derived dendritic cells (BMDCs) survive better under CD40 and RANKL 
stimulation due to the enhanced production of anti-apoptotic Bcl-2 and Bcl-x (Kool et al., 2011).  
A20-deficient B cells also produce more Bcl-x and, therefore, are more resistant to Fas-mediated 
cell death (Tavares et al., 2010).  Similarly, A20-deficient mast cells are resistant to LPS- and IL-
33-mediated apoptosis due to enhanced Bcl-2 and Bcl-x production (Heger et al., 2014). In 
summary, the function of A20 in apoptosis is highly dependent on the cell type as well as the 
balance between its anti-apoptotic properties and its regulation of anti-apoptotic genes. 
1.5.2 Function of A20 in NF-κB signaling  
Activation of the NF-κB signaling cascade is dependent on the K63-linked polyubiquitination of 
various signaling molecules such as TRAF6, RIP1, and NEMO. As an ubiquitin-editing enzyme, 
A20 target these proteins for deubiquitination and inactivation, thereby downregulating the NF-
κB signaling (Fig. 9). Upon TNF stimulation, A20 expression is rapidly induced in an NF-κB-
dependent way and targets RIP1, which is ubiquitinated with K63-linked polyubiquitin chains by 
cIAP1/2, for inactivation in two sequential steps (Bertrand et al., 2008). As a DUB, A20 first 
inactivate RIP1 by removing the K63-linked polyubiquitin chains. Then, utilizing its E3 ligase 
activity, A20 attaches K48-linked polyubiquitin chains to RIP1 for proteasome-mediated 
degradation (Wertz et al., 2004). The E3 ligase activity of A20 is dependent on the fourth zinc 
finger domain (ZnF4). Thus, A20 plays dual roles in ubiquitin-editing of RIP1 via its DUB and 
E3 activities. In addition to RIP1, A20 inhibits TNF-induced NF-κB signaling by 
deubiquitinating NEMO (Mauro et al., 2006). Recently, linear polyubiquitination, which is 
generated by the E3 ligase complex called linear ubiquitin chain assembly complex (LUBAC), is 
considered to be important for canonical NF-κB activation (Tokunaga et al., 2009; Tokunaga et 
al., 2011; Ikeda et al., 2011). A20 can also disrupt TNF-induced interaction between LUBAC 
and NEMO by competitive binding to the linear polyubiquitin through its ZnF7 domain, 
resulting in NF-κB inhibition (Verhelst et al., 2012; Tokunaga et al., 2012). 
Tnfaip3-/- mice are protected from lethal inflammation by crossing with Myd88-/- mice, 
suggesting that the spontaneous inflammation in A20-deficient mice is driven by TLR signaling. 
Consistently, treatment with broad-spectrum antibiotics protects Tnfaip3
-/-
 mice from lethal 
inflammation, indicating that A20-deficiency causes hyperactivation of the TLR signaling to 
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commensal intestinal flora (Turer et al., 2008). Thus, A20 might be a negative regulator of the 
TLR signaling. In the absence of A20, bone marrow-derived macrophages (BMDMs) exhibit 
elevated and persistent NF-κB activation and produce more inflammatory cytokines in response 
to LPS, suggesting that A20 is a negative regulator of the TLR4 signaling (Boone et al., 2004). 
As a DUB, A20 downregulates LPS-induced NF-κB signaling through removing K63-linked 
polyubiquitin chains from TRAF6. Deubiquitination of TRAF6 by A20 is also an important 
mechanism in the inhibition of signaling pathways induced by IL-1 or TGF-β (Jung et al., 2013; 
Shembade et al., 2010). In addition to deubiquitination, A20 can also inhibit LPS-induced NF-
κB signaling by disrupting the ubiquitination process. For example, A20 inhibits the E3 ligase 
activities of TRAF6, TRAF2, and cIAP1 by disrupting their interaction with the E2 ubiquitin 
conjugating enzymes (Shembade et al., 2010). 
A20 expression can be induced by treatment with IL-17 (Garg et al., 2013). Upon IL-17 
stimulation, A20-deficient cells display enhanced expression of inflammatory genes. 
Mechanistically, in response to IL-17, A20 interacts and deubiquitinates TRAF6 and restricts IL-
17-induced NF-κB and MAPK pathways (Garg et al., 2013). 
A20 can also inhibit the NF-κB signaling induced by nucleotide-binding oligomerization 
domain containing 2 (NOD2), which is activated by muramyl dipeptide (MDP), a product of 
bacterial cell wall peptidoglycan (Hitotsumatsu et al., 2008). NOD2-mediated IKK activation is 
critically dependent on the K63-linked polyubiquitination of RIP2. Using its DUB activity, A20 
inhibits NOD2 signaling by romoving K63-linked polyubiquitin chains from RIP2. In response 
to MDP, A20-deficient cells display enhanced RIP2 ubiquitination, NF-κB activation, and 
production of proinflammatory cytokines. In vivo, A20-deficient mice exhibit stronger responses 
to MDP challenge than control mice, as evidenced by the increased serum levels of IL-6 
(Hitotsumatsu et al., 2008).  
A20 exerts its inhibitory functions towards NF-κB signaling with the help of other 
proteins, including Tax1 binding protein 1 (TAX1BP1), Itch, Ring finger protein 11 (RNF11), 
A20 binding and inhibitor of NF-κB (ABIN-1), and YMER (Fig. 9). Together, these proteins 
form a complex termed A20 ubiquitin-editing complex. 
TAX1BP1 was indentified as an A20-interacting protein with yeast two-hybrid screen 
and it was found to inhibit TNF induced apoptosis (De et al., 1999). Similar to Tnfaip3
-/-
 mice, 
Tax1bp1
-/-
 mice are born normal, but die prematurely due to inflammation, and are 
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hypersensitive to TNF and IL-1 (Iha et al., 2008). Both Tnfaip3
-/-
 and Tax1bp1
-/-
 MEFs exhibit 
enhanced and prolonged NF-κB activation in response to TNF or IL-1. Given that TAX1BP1 
lacks a DUB domain and has a UBD in its C-terminus, it is possible that TAX1BP1 inhibits NF-
κB through A20. Indeed, TAX1BP1 serves as an adaptor to bridge A20 with TRAF6 or RIP1, 
resulting in reduced ubiquitination of the substrates (Iha et al., 2008). In the absence of 
TAX1BP1, the interaction of A20 with TRAF6 or RIP1 is compromised.  
Upon TNF stimulation, TAX1BP1 interacts with Itch, which is also important for 
recruiting A20 to RIP1 and the concomitant RIP1 deubiquitination (Shembade et al., 2008). 
Downregulating Itch with siRNA substantially impaired A20-mediated degradation of RIP1. 
Similar to Tnfaip3-/- and Tax1bp1-/- MEFs, Itch-/- MEFs display enhanced and prolonged NF-κB 
signaling induced by TNF or IL-1. Itch
-/- 
mice have severe immunological defects, including 
lymphoid hyperplasia in peripheral lymphoid organs and spontaneous inflammation in skin and 
lungs, and die by 35 weeks after birth. However, unlike Tnfaip3-/- mice, in which the lethal 
inflammation is independent of the adaptive immune response, Itch
-/- 
mice are protected from the 
deleterious inflammation by crossing with Rag1-/- mice, indicating that lymphocytes are required 
for the autoimmunity of Itch
-/- 
mice (Shembade et al., 2008). 
In response to TNF, TAX1BP1 and Itch inducibly interact with RNF11 (Colland et al., 
2004; Shembade et al., 2009). Upon TNF stimulation, downregulation of RNF11 enhances NF-
κB signaling whereas overexpression of RNF11 inhibits NF-κB activation, indicating that 
RNF11 is a negative regulator of NF-κB signaling. Consistently, knockdown of RNF11 with 
siRNA increases levels of RIP1 and TRAF6 ubiquitination upon TNF or LPS stimulation, 
respectively. Importantly, RNF11 is required for A20 to bind and degrade RIP1. In addition, 
RNF11 interacts with RIP1 and their interaction is impaired in the absence of TAX1BP1 or Itch 
suggesting that RNF11 is a component of the A20 ubiquitin-editing protein complex consisting 
of A20, TAX1BP1, and Itch (Shembade et al., 2009).  
ABIN-1 and YMER are also characterized as A20 interacting proteins (Heyninck et al., 
1999; Bohgaki et al., 2008). Overexpression of either ABIN-1 or YMER inhibits NF-κB 
signaling. Serving as an adaptor molecule, ABIN-1 is required for A20 to bind and 
deubiquitinate NEMO (Mauro et al., 2006). YMER also inhibits NF-κB signaling in 
collaboration with A20. YMER interacts with RIP1 and, as a scaffold, links A20 with K63-
linked polyubiquitin chains for deubiquitination. 
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Figure 9. Regulation of the canonical NF-κB pathway by A20 
A20 inhibits the canonical NF-κB pathway by removing K63-linked ubiquitin molecules from RIP1, RIP2, TRAF6 
and/or NEMO under different stimuli. A20 also induces proteasome-dependent degradation of RIP1 by adding K48-
linked polyubiquitin chains.  In addition, A20 can also excert its inhibitory function by disrupting E2/E3 interaction 
and mediating degradation of E2 enzymes.  
1.5.3 Function of A20 in different cell populations 
Tnfaip3
-/-
 mice succumb prematurely due to unrestricted inflammation in multiple organs and 
cachexia as a result of uncontrolled NF-κB activation (Lee et al., 2000). The spontaneous 
inflammation and premature lethality of Tnfaip3
-/-
 mice precludes the use of them for 
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experimentally induced disease models. In order to overcome these drawbacks, conditional gene 
targeting was applied to specifically ablate A20 in certain kinds of tissues. 
Intestinal epithelial cell (IEC)-specific A20-deficient mice 
To study IEC-specific function of A20, A20 was selectively deleted in IECs of the A20
IEC-KO
 
mice, which were generated by breeding of A20
fl/fl
 mice with Villin-Cre transgenic mice 
(Vereecke et al., 2010). Unlike Tnfaip3-/- mice, A20IEC-KO mice develop normally and do not 
show spontaneous colitis. However, A20
IEC-KO
 mice are susceptible to dextran sulphate sodium 
(DSS) induced colitis, which is triggered by enhanced IEC apoptosis mediated by TNF. 
Apoptosis of IECs further leads to the breakdown of intestinal barrier, infiltration of commensal 
intestinal bacteria, and ultimately, systemic inflammation and lethality. These findings are 
confirmed by another study with mice overexpressing A20 specifically in IECs (Kolodziej et al., 
2011). Collectively, in this study, A20 is identified as an anti-apoptotic protein in IECs and is 
important for epithelial barrier integrity. 
B cell-specific A20-deficient mice 
Inactive A20 mutations are frequently discovered in B-cell lymphomas (Kato et al., 2009). To 
study the function of A20 in B cells, three strains of A20
BC-KO
 mice, in which A20 was 
specifically deleted in B lymphocytes, were generated by crossing A20
fl/fl
 mice with CD19-Cre 
transgenic mice by three independent groups. A20
BC-KO
 mice develop symptoms of 
autoimmunity, including the production of autoantibodies, due to the accumulation of immature 
and germinal center B cells. In contrast to the well-known anti-apoptotic function of A20, A20 
deficient B cells are resistant to FasL-mediated cell death, probably due to increased expression 
of anti-apoptotic Bcl-x (Tavares et al., 2010). Another A20
BC-KO
 mouse strain also displays 
autoimmune syndrome, although only in aged mice (Chu et al., 2011). Consistently, we also 
reported that B cell-specific A20-deficient mice, which were generated independently by us, 
produced autoantibodies and A20-deficient B cells were hyperactive illustrated by enhanced 
proliferation upon activation (Hovelmeyer et al., 2011). 
Myeloid cell-specific A20-deficient mice 
A20 was specifically deleted in cells of myeloid origin, including macrophages and granulocytes, 
in LysM-Cre A20
fl/fl
 (A20
myel-KO
) mice (Matmati et al., 2011). These mice develop human 
rheumatoid arthritis-like spontaneous polyarthritis that is associated with the presence of 
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collagen-specific autoantibodies and proinflammatory cytokines in serum. The phenotype is TNF 
independent and is IL-6 and TLR4-MyD88 dependent. A20-deficient macrophages display 
sustained NF-κB activation and produce more proinflammatory cytokines upon LPS stimulation. 
The destructive polyarthritis in A20myel-KO mice is ameliorated by treatment with IL-6-
neutralizing antibodies and is almost completely abolished by crossing to a MyD88-deficient 
background. In addition, myeloid A20-deficiency also enhances osteoclast differentiation and 
activation (Matmati et al., 2011). 
 In contrast to its susceptibility to autoimmunity, A20
myel-KO
 mice are protected from 
lethal influenza A virus infection due to increased cytokine and chemokine production (Maelfait 
et al., 2012).  
Dendritic cell (DC)-specific A20-deficient mice 
Three DC-specific A20 deficient mouse strains were generated independently by crossing A20fl/fl 
mice with CD11c-Cre transgenic mice by three groups (Hammer et al., 2011; Kool et al., 2011). 
In contrast to the premature lethality of globally A20-deficient mice, A20DC-KO mice do not show 
defects in survival. However, A20
DC-KO
 mice develop splenomegaly and lymphadenopathy. A20-
deficient DCs spontaneously mature and produce high levels of proinflammatory cytokines. 
Besides, A20-deficient DCs are resistant to apoptosis due to increased Bcl-2 and Bcl-x 
production (Kool et al., 2011). These A20
DC-KO 
mouse strains also show different diease 
phenotypes. One strain develops nephritis, antiphospholipid syndrome, and autoimmune arthritis, 
resembling human systemic lupus erythematosus (SLE) (Kool et al., 2011). Another strain 
develops lymphocyte-dependent colitis, enthesitis, and seronegative ankylosing arthritis, which 
are conditions typical of human inflammatory bowel disease (IBD) (Hammer et al., 2011). Our 
A20
DC-KO 
mice develop spontaneous hepatitis. The differences can be attributed to the different 
genetic backgrounds, the different gene-targeting strategies, and/or the divergent microbiota in 
the two strains (Honda and Littman, 2012; Hammer and Ma, 2013). Nevertheless, the three 
studies clearly show that A20 expression in DCs preserves immune homeostasis under steady-
state conditions. 
Keratinocyte-specific A20-deficient mice 
Keratinocyte-specific A20 deficiency was achieved in Krt14-Cre A20
fl/fl
 (A20
K-KO
) mice 
(Lippens et al., 2011). A20K-KO mice show no signs of spontaneous skin inflammation but 
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develop keratinocyte hyperproliferation and ectodermal organ abnormalities, such as disheveled 
hair, longer nails and sebocyte hyperplasia. These phenotypes are also present in mice with 
dysregulated ectodysplasin A receptor-mediated signaling. Indeed, A20 is found to be an 
inhibitor of EDAR-triggered NF-κB signaling (Lippens et al., 2011).  
Mast cell-specific A20-deficient mice 
Recently, mast cell-specific A20 deficient mice were generated by crossing A20
fl/fl
 mice with 
Mcpt5-Cre transgenic mice (Heger et al., 2014). Although A20 inhibits TLR-, IL33R-, and 
IgE/FcεR1-induced NF-κB activation in mast cells, ablation of A20 in mast cells does not induce 
spontaneous pathology. However, mast cell-specific A20 deficient mice are more sensitive to 
allergic airway inflammation and collagen-induced arthritis (Heger et al., 2014). 
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2. Aims 
Astrocytes have been shown to play diverse roles in the pathogenesis and development of EAE.  
To gain more insight into the role of astrocyte in EAE, we studied the function of astrocyte-
derived A20 and FasL in EAE. 
2.1 Function of astrocytic A20 in EAE 
To study the function of astrocytic A20 in EAE, we generated mice lacking A20 in either 
neuroectodermal cells (Nestin-Cre A20
fl/fl
 mice) or astrocytes (GFAP-Cre A20
fl/fl 
mice) and 
challenged them with EAE. EAE severity of these mice was compared with that of A20
fl/fl
 
control mice, respectively, based on clinical symptoms. In addition, we also analyzed the 
inflammation in the spinal cord by FACS, RT-PCR, and histology. Since astrocytes play a key 
role in EAE pathogenesis by producing chemokines, we studied the influence of A20 on 
chemokine production in astrocytes. Finally, we studied the impact of A20 on signaling 
pathways in astrocytes.  
2.2 Function of astrocytic FasL in EAE 
To investigate the influence of astrocyte-derived FasL on EAE, we generated GFAP-Cre FasL
fl/fl
 
mice, in which FasL was specifically and efficiently ablated in astrocytes, and challenged them 
with EAE. EAE severity was evaluated by monitoring clinical symptoms. Further, we studied the 
influence of astrocyte-specific FasL deficiency on the number, composition, and apoptosis of 
infiltrating T cells in the spinal cord. Inflammation in the spinal cord was further studied by RT-
PCR and histology. Finally, we investigated the direct impact of astrocytic FasL on T cell 
apoptosis using an in vitro co-culture system. 
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3.Materials and methods 
3.1.Materials  
3.1.1 Chemicals used for animal experiments 
 
Embedding medium    Sakura Finetek Europe BV, Zoeterwoude Netherlands 
     (TissueOCTTM Tek ® compound) 
Freund's adjuvant, Complete              Sigma-Aldrich, Steinheim, Germany 
Isoflurane (Forene ®)   Abbott, Wiesbaden, Germany 
M. tuberculosis H37 RA   Difco Laboratories, Detroit, USA 
Pertussis toxin                                     Sigma-Aldrich, Steinheim, Germany   
2-methylbutane    Carl Roth, Karlsruhe, Germany 
4% paraformaldehyde (PFA)   Carl Roth, Karlsruhe, Germany 
 
3.1.2 Materials for cell culture  
Cell culture was performed in a sterile environment under a laminar flow hood. The cell culture 
media were prewarmed in a 37 °C water bath before use. Cells were kept in an incubator at 37 
°C, 5% CO2 and 60% of water vapor. Plastic materials for cell culture were purchased from 
Greiner Bio-One (Frickenhausen, Germany) and Carl Roth (Karlsruhe, Germany). 
Astrocyte culture medium DMEM (PAA Laboratories GmbH, Pasching, 
Austria), fetal calf serum (FCS, PAA 
Laboratories GmbH, Pasching, Austria), 100 U 
Penicillin / streptomycin (PAA Laboratories GmbH, 
Pasching, Austria) 
Hank's  medium   PAA Laboratories, Pasching, Austria  
 
Neuron culture medium Neurobasal Medium  (Gibco, Grand island, USA), 
B-27 Supplements (Gibco, Grand island, USA), L-
Glutamine (Gibco, Grand island, USA), 100 U 
Penicillin / streptomycin (PAA Laboratories GmbH, 
Pasching, Austria) 
 
Opti-MEM                Gibco, Grand island, USA 
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PBS      PAA Laboratories GmbH, Pasching, Austria 
Poly-D-lysine                                     Sigma-Aldrich, Steinheim, Germany  
poly-L-lysine                                      Sigma-Aldrich, Steinheim, Germany 
Trypan blue                Sigma-Aldrich, Steinheim, Germany 
Trypsin     PAA Laboratories GmbH, Pasching, Austria 
 
3.1.3 Materials for molecular biology 
 
β-mercaptoethanol    Carl Roth, Karlsruhe, Germany 
DNeasy Blood and Tissue Kit  Qiagen, Hilden, Germany  
dNTP      Invitrogen, Karlsruhe, Germany 
DTT      Invitrogen, Karlsruhe, Germany 
EasyDNA kit    Invitrogen, Karlsruhe, Germany 
Ethanol (95%, 100%)   Pharmacy of the University Hospital Magdeburg 
HotStar Taq     Qiagen, Hilden, Germany 
Oligo-dT     Invitrogen, Karlsruhe, Germany 
PCR Buffer, 10x    Qiagen, Hilden, Germany 
RNeasy Mini Kit    Qiagen, Hilden, Germany 
Primers for PCR             Eurofins MWG Operon, Ebersberg, Germany 
Primers for qRT-PCR              Applied Biosystems, Darmstadt, Germany  
siRNAs                                   Invitrogen, Karlsruhe, Germany 
RNAiMAX Transfection Reagent Invitrogen, Karlsruhe, Germany 
Sterile distilled water    Berlin Chemie AG, Berlin, Germany 
Superscript II Reverse  Invitrogen, Karlsruhe, Germany 
Transcriptase    
TaqMan Universal PCR master mix Applied Biosystems, Darmstadt, Germany 
5x First Strand Buffer   Invitrogen, Karlsruhe, Germany 
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Table 1 Genotyping primers 
 
Mouse strain               primer sequence (5 '→ 3')    amplicon size  
GFAP-Cre FasL
fl/fl 
mice 
GFAP-Cre Sense        5'-GACACCAGACCAACTGGTAATGGTAGCGAC-3'     850bp          
Antisense  5'-GCATCGAGCTGGGTAATAAGCGTTGGCAAT-3'      
Del-FasL Sense 5'- GGAGTTGAACGAGTAGCCTC -3'                               500bp  
Antisense  5'- GTACTTCTTCTGATAAGGACC -3'  
FasL
 
Sense              5'-ATTAATTACAGTGAAGAGATGG-3'                            660bp 
Antisense  5'- GTACTTCTTCTGATAAGGACC -3'  
FasL
wt/wt
 mice amplicon size = 660 bp, FasL
fl/fl 
mice amplicon size = 700 bp 
GFAP-Cre A20
fl/fl
 mice 
GFAP-Cre Sense        5'-GACACCAGACCAACTGGTAATGGTAGCGAC-3'      850bp   
Antisense  5'-GCATCGAGCTGGGTAATAAGCGTTGGCAAT-3'    
A20
 
Sense              5'-AGTCTGGGACTGGATGTAGC-3'                                  300bp 
Antisense  5'-CTGGCTAAGGCCTTGATACC-3'   
A20
wt/wt
 mice amplicon size = 300 bp, A20
fl/fl 
mice amplicon size = 419 bp 
Nestin-Cre A20
fl/fl
 mice 
Nestin-Cre Sense        5'-TCCCTTCTCTAGTGCTCCACGTCC-3'                          650bp 
Antisense  5'-TCCATGAGTGAACGAACCTGGTCG-3'       
A20
 
Sense              5'-AGTCTGGGACTGGATGTAGC-3'                                  300bp 
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Antisense  5'-CTGGCTAAGGCCTTGATACC-3'   
A20
wt/wt
 mice amplicon size = 300 bp, A20
fl/fl 
mice amplicon size = 419 bp 
Synapsin-Cre A20
fl/fl
 mice 
Synapsin-Cre Sense    5'-CCAGCACCAAAGGCGGG-3'                                 450bp 
Antisense  5'-TGCATCGACCGGTAATGCAG-3'       
A20 Sense              5'-AGTCTGGGACTGGATGTAGC-3'                              300bp 
Antisense  5'-CTGGCTAAGGCCTTGATACC-3'   
A20
wt/wt
 mice amplicon size = 300 bp, A20
fl/fl 
mice amplicon size = 419 bp 
 
 
3.1.4 Materials for proteomics 
 
Blotting grade milk powder    Carl Roth, Karlsruhe, Germany 
Bradford reagent     Bio-Rad, Munich, Germany  
BSA      Sigma-Aldrich, Steinheim, Germany 
Filter paper     Carl Roth, Karlsruhe, Germany 
Gel running buffer pH 8.3     25 mM Tris, 0.1% sodium dodecyl sulfate (both from 
       Carl Roth, Karlsruhe, Germany), 250 mM glycine  
(Sigma  Aldrich, Steinheim, Germany) 
 
Polyvinylidene fluoride (PVDF)  Millipore, Schwalbach, Germany 
Membrane Immobilon P 
 
Protein marker    Fermentas, St. Leon-Rot, Germany 
5 × lane marker reducing sample Thermo scientific, MA, USA 
buffer 
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RIPA buffer  50 mM Tris / HCl pH 7.5, 100 mM NaCl, 5 mM EDTA, 
10 mM H2PO4 (all from Carl Roth, Karlsruhe, 
Germany), 1% Triton X-100, 0.25% deoxycholic acid, 
Protease inhibitor cocktail, 20 mM sodium fluoride, 0.2 
Mm phenyl methyl sulfonyl fluoride, 1mM Sodium 
molybdate, 20 mM glycerol-2-phosphate, 1 mM sodium 
phosphate buffer (all from Sigma-Aldrich, 
Steinheim,Germany), 10% glycerol (Calbiochem, 
Darmstadt, Germany), PhosStop (Roche, Mannheim, 
Germany) RIPA buffer  
SDS-polyacrylamide separating gel Distilled water, 8 to 10% acrylamide 30% (Applichem, 
Darmstadt, Germany), 0.4 M Tris, 0.1% Sodium dodecyl 
sulfate (both from Carl Roth, Karlsruhe, Germany), 0.1% 
ammonium persulfate, 0.1% TEMED (both from Sigma-
Aldrich, Steinheim, Germany) 
SDS-polyacrylamide stacking gel  Distilled water, 5% acrylamide 30% (Applichem, 
Darmstadt, Germany), 0.17 M Tris, 0.1% Sodium 
dodecyl sulfate (both from Carl Roth, Karlsruhe, 
Germany), 0.1% ammonium persulfate, 0.1% TEMED 
(both from Sigma-Aldrich, Steinheim, Germany) 
TBS-Tween 20, pH 7.4 20 mM Tris, 140 mM NaCl (both from Carl Roth, 
Karlsruhe, Germany), 0.1% (v / v) Tween 20 (Sigma -
Aldrich, Steinheim, Germany)  
Transfer buffer pH 8.4 25 mM Tris, 0.1% sodium dodecyl sulphate (both from 
Carl Roth, Karlsruhe, Germany), 500 mM glycine 
(Sigma-Aldrich, Steinheim, Germany), 20% Methanol 
(J.T. Baker, Deventer, Netherlands) 
 
 
Table 2. Antibodies for Western blotting and Immunoprecipitation (IP) 
Primary antibody           Blocking solution    Antibody dilution  
All antibodies were obtained from (Cell Signaling Technology Danvers, MA, USA) unless stated 
otherwise. 
Anti-A20 (# sc-166692)              1% BSA    1:500  
(Santa Cruz biotechnology,                1% milk powder 
Heidelberg, Germany) 
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Anti-ERK1/2 (# 4370)    5% BSA    1:1000  
Anti-GAPDH (# 5174)  1% BSA    1:1000  
     1% milk powder  
  
Anti-HDAC (# 5356)   1% BSA    1:1000  
     1% milk powder 
Anti-IκBα (# 9242)   5% BSA    1:1000 
Anti-JNK (# 9258)              5% BSA    1:1000  
Anti-p38 (# 9212)   5% BSA    1:1000  
Anti-phospho-ERK1/2 (# 4377)   5% BSA    1:1000  
Anti-phospho-IκBα (# 9246)  5% BSA    1:1000   
Anti-phospho-JNK (# 4668)             5% BSA    1:1000  
Anti-phospho-p38 (# 9211)      5% BSA    1:1000  
Anti-phospho-STAT1 (# 8826) 5% BSA    1:1000  
Anti-phospho-STAT1 (# 9167) 5% BSA    1:1000  
Anti-STAT1 (# 9172)              5% BSA    1:1000  
Anti-tubulin (# 2148)   5% BSA    1:1000  
 
 
Secondary antibodies for Western Blotting 
Polyclonal Rabbit Anti-Mouse Immunoglobulins/HRP (# P 0260) Dako, Glostrup, Denmark 
Polyclonal Swine Anti-Rabbit Immunoglobulins/HRP (# P 0399) Dako, Glostrup, Denmark 
 
Table 3. Antibodies for flow cytometric analysis 
Antibody          Clone  
APC-anti-mouse CD4 (rat)                                                                   (RM4-5) 
APC-rat-IgG isotype control       (R35-95) 
FITC-anti-mouse B220 (rat)                       (RA3-6B2) 
FITC-anti-mouse CD3 (rat)                             (G4.18) 
FITC-anti-mouse CD11b (rat)       (M1/70) 
FITC-anti-mouse CD11c (hamster)                   (V418) 
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FITC-anti-mouse CD25 (rat)                             (7D4) 
FITC-anti-mouse CD62L (rat)       (MEL-14) 
FITC-anti-mouse F4/80 (rat)                       (BM8) 
FITC-anti-mouse Ly6G (rat)        (RB6-8C5)  
FITC-hamster-IgG isotype control       (HTK888) 
FITC-rat-IgG isotype control       (A95-1) 
PE-anti-mouse CD11b (rat)                   (M1/70) 
PE-anti-mouse CD19 (rat)                   (1D3) 
PE-anti-mouse CD44 (rat)        (IM7) 
PE-anti-mouse CD69 (rat)        (H1.2F3) 
PE-anti-mouse CD95 (hamster)                  (Jo2) 
PE-anti-mouse CD178.1 (mouse)                  (KAY-10) 
PE-anti-mouse Foxp3 (rat)                                   (R16-715) 
PE-anti-mouse GM-CSF (rat)                     (MP1-22E9) 
PE-anti-mouse IFN-γ (rat)                        (XMG1.2) 
PE-anti-mouse IL-17A (rat)                               (TC11-18H10)  
PE-anti-mouse Ly6C (rat)                   (AL-21) 
PE-anti-mouse NK1.1 (rat)                   (PK136) 
PE-hamster-IgG isotype control       (G235-2356) 
PE-rat-IgG isotype control       (A95-1) 
PECy5-anti-mouse CD8α (rat)       (53-6.7) 
PECy5-rat-IgG isotype control      (A95-1) 
V450-anti-mouse CD45 (rat)                       (30-F11) 
V450-rat-IgG isotype control                      (MOPC-21) 
PE-anti-mouse Annexin V  
7 AAD  
(All antibodies obtained from BD Biosciences, Heidelberg, Germany and used at a concentration 
of 1µg/ 1x106 cells) 
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Peptides  
(MOG)35-55 peptide                                          JPT, Berlin, Germany 
 
Kits 
Active Caspase-3 mAb Apoptosis kit   BD Biosciences, Heidelberg, Germany  
Anti-O4 MicroBeads                                                  Miltenyi Biotec, Bergisch Gladbach, 
Germany 
CD4 T cell isolation kits, mouse Miltenyi Biotec, Bergisch Gladbach, 
Germany 
NE-PER Nuclear and Cytoplasmic    Thermo scientific, MA, USA 
Extraction Reagents  
Neuronal Tissue Dissociation Kit Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Pierce ECL Plus Western Blotting substrate     Thermo scientific, MA, USA 
Vybrant Apoptosis Assay                                   Invitrogen, Karlsruhe, Germany 
    
3.1.5 Instruments 
Bio-Rad Mini protein system    Bio-Rad, California, USA 
Centrifuge 5415R      Eppendorf, Hamburg, Germany 
Chemo Cam Luminescent Image Analysis system  INTAS, Göttingen, Germany 
Coverslip (for Neubauer counting chamber)   Carl Roth, Karlsruhe, Germany 
Documentation station     Herolab GmbH, Wiesloch, Germany 
FACS Canto II      BD Biosciences, Heidelberg, Germany 
FACSVantage cell sorter           BD Biosciences, Heidelberg, Germany 
Incubator       Heraeus, Hanau, Germany 
Laboratory balance     Sartorius, Göttingen, Germany 
Laminar flow hood     Heraeus, Hanau, Germany 
LightCycler 480 instrument    Roche, Mannheim, Germany 
Microscope                            Nikon, Tokyo, Japan 
PCR machine       Peq lab, Erlangen, Germany 
pH meter                    SHOTT, Mainz, Germany 
Pipette       Eppendorf, Hamburg, Germany 
Pipette boy       INTEGRA, Fernwald, Germany 
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Power PAC 200      Bio-Rad, California, USA 
Semi Dry blotter      Peq lab, Erlangen, Germany 
Shaker                                             IKA-Werke, Staufen, Germany 
Thermomixer compact     Eppendorf, Hamburg, Germany   
Vortex Mixer                                        IKA-Werke, Staufen, Germany 
3.1.6 Animals  
Nestin-Cre
+/-
 A20
fl/fl
,
 
glial fibrillary acidic protein (GFAP)-Cre
+/-
 A20
fl/fl
, and Synapsin-Cre
+/-
 
A20
fl/fl
 mice were generated by crossing C57BL/6 Nestin-Cre, GFAP-Cre, and Synapsin-Cre 
mice, respectively, with C57BL/6 A20
fl/fl
 mice in our animal facility. GFAP-Cre
+/-
 FasL
fl/fl
 mice 
were generated by crossing C57BL/6 GFAP-Cre transgenic mice with C57BL/6 FasL
fl/fl
 mice 
(Karray et al., 2004) and the colony was maintained by breeding of GFAP-Cre+/- FasLfl/fl mice 
with GFAP-Cre
-/-
 FasL
fl/fl
 mice.  C57BL/6 WT mice were obtained from Harlan (Borchen, 
Germany). Animal care and experimental procedures were performed according to European 
regulations and approved by state authorities (Landesverwaltungsamt Halle, Germany). 
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3.2 Methods 
 
3.2.1 Genotyping of the mouse strains 
For genotyping of mice, a tissue sample of the tail tip was cut and transferred to a 2 ml 
Eppendorf tube. Genomic DNA was isolated from mouse tail using easyDNA kit (Invitrogen, 
Karlsruhe, Germany) according to instructions of the manufacturer. PCR was performed using 
primers targeting Nestin-Cre, GFAP-Cre, Synapsin-Cre, FasL
fl/fl
 and A20
fl/fl
 respectively, as 
indicated in Table 1. 
3.2.2 Induction of EAE 
4 mg of MOG35-55 (MEVGWYRSPFSRVVHLYRNGK) peptide dissolved in 2 ml of PBS was 
emulsified with 2 ml of complete Freund's adjuvant supplemented with 20 mg of killed 
Mycobacterium tuberculosis. Active EAE was induced in 8-12 weeks old mice by subcutaneous 
(s.c.) immunization with 200 µl of emulsified MOG35-55 peptide. In addition, mice also received 
two intraperitoneal (i.p.) injections of 200 ng pertussis toxin dissolved in 200 µl PBS, at the time 
of immunization as well as 48 h thereafter.  
3.2.3 Assessment of EAE 
Clinical signs of EAE were monitored daily and scored according to a scale of severity from 0 to 
5 as follows: 0, no sign; 0.5, partial tail weakness; 1, limp tail; 1.5, limp tail and slowing of 
righting; 2, marked slowing of righting and partial hind limb weakness; 2.5, dragging of hind 
limb(s) without complete paralysis; 3, complete paralysis of at least one hind limb; 3.5, hind limb 
paralysis and slight weakness of forelimbs; 4, forelimb weakness; 5, moribund or dead. The 
scoring of EAE mice was double blind. Daily clinical scores were calculated as the average of all 
individual disease scores within each group.  
3.2.4 Isolation of leukocytes from spinal cord 
Animals were anesthetized with isoflurane (Baxter, Deerfield, IL). Spinal cord was isolated and 
subject to Percoll gradient centrifugation (GE Healthcare, Freiburg, Germany) for leukocyte 
separation. Cell pellet was resuspended with 9 ml Percoll at a density of 1.098 g. Then, 5 ml 
Percoll at a density of 1.22 g was carefully loaded at the bottom. A density gradient was created 
by overlaying Percoll densities of 1.07 g, 1.05 g, 1.03 g and 1.00 g successively. The Percoll 
gradient was centrifuged at 1,200 g for 20 min with rapid start and slow stop. The upper layers of 
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densities 1.00 g and 1.03 g were carefully removed and discarded. The upperlayers of densities 
1.05, 1.07, and 1.098 were carefully harvested and transferred to a new 50 ml Falcon tube. Cells 
were washed with cell culture medium containing 3% FCS by centrifugation. Cell pellet of 
leukocytes was resuspended in cell culture medium. Number of cells was counted using a 
hemocytometer. 
3.2.5 Flow Cytometry  
For staining of extracellular markers, 1 × 10
6
 cells were transferred to a FACS tube containing 3 
ml PBS (4 °C) and centrifuged at 1,200 rpm for 6 min at 4 °C. After discarding the supernatant, 
1 µg CD16/32 antibody diluted in 50 µl PBS was added and incubated at 4 °C for 10 min to 
block non-specific binding sites. Subsequently, specific antibodies (as indicated in Table 3) were 
added to cells and incubated in the dark for 30 min at 4 °C. After staining, the cells were washed 
by centrifugation in 3 ml PBS (4 °C). The cell pellet was resuspended in 200 µl PBS (4 °C) and 
measured with a flow cytometer within 4 h. For detection of intracellular proteins, cells were 
stimulated with phorbol 12-myristate 13-acetate (PMA, 50 ng / ml) and Ionomycin (500 ng / ml) 
and incubated at 37 °C for 3 h to increase cytokine production. Then, 1 µl / ml GolgiPlug was 
added to block intracellular protein transport and enrich protein concentration in the Golgi 
complex. After an incubation period of 12 hours, cells were washed twice with 3 ml PBS (4 °C). 
Then, cells were incubated with CD16/32 to block non-specific binding for 10 min at 4 °C. 
Thereafter, extracellular proteins were stained with specific antibodies for 20 minutes at 4 °C. 
After washing twice with 3 ml PBS (4 °C), intracellular staining was performed. The cells were 
fixed in 250 µl of Cytofix / Cytoperm for 20 minutes at 4 °C and permeabilized with 1 ml of 1 × 
Perm/Wash. The cells were then stained with specific antibodies (as indicated in Table 3) diluted 
in 1 × Perm/Wash and incubated for 30 min at 4 °C. After 2 washes with 1 × Perm/Wash, the 
cells were centrifuged and resuspended in 200 µl PBS (4 °C). Stained cells were measured with a 
FACSCanto II (BD Biosciences) flow cytometer and the analysis was performed with the 
FACSDiva 6 software (BD Biosciences). 
3.2.6 Astrocyte culture 
1- to 2-day-old new born mice were sterilized with 70% ethanol. Then, heads of mice were cut 
and put in astrocyte culture medium (DMEM supplemented with 10% FCS and 1% 
penicillin/streptomycin), and tails were cut for genotyping. Brains were removed and 
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mechanically dissociated with 70 µm cell strainers to generate single cell suspension. Cells were 
then cultured for 9 days in a cell incubator. Medium was changed every 3 days. On day 9, cells 
were shaken on a shaker to remove contaminating microglia and then washed intensively with 
PBS. Thereafter, adherent cells were harvested by trypsinization, and subcultured in new flasks. 
To eliminate microglia from astrocyte cultures, cells were harvested from astrocyte cultures and 
stained with rat anti-mouse CD11b-PE. Astrocytes (CD11b
-
) were separated from CD11b
+
 
microglia with a FACSVantage cell sorter (BD). For the detection of FasL expressed on the 
surface of astrocytes, mixed astrocyte/microglia cultures were stained with mouse anti-mouse 
FasL-PE and CD11b-FITC. Controls were stained with isotype-matched control antibodies. 
3.2.7 Neuron culture 
Pregnant female mice were sacrificed by cervical dislocation at gestational day 18.5, and brains 
of pups were isolated. After carefully removing meninges under a macroscope, cortices were 
excised into small pieces and then incubated with 400 µl trypsin for 20 minutes at 37 °C. 
Trypsinization was stopped by adding 400 µl of trypsin inhibitor. The tissue was washed twice 
with 800 µl neurobasal medium to remove remaining trypsin and trypsin inhibitor and then 
mechanically dissociated with syringes to generate single cell suspension. Cells of each 
embryonic brain were counted and seeded in flasks coated with poly-D-lysine in Neurobasal 
medium supplemented with 2% B27, 500 µM L-glutamine, and 1% penicillin/streptomycin. 
Every 4 days, half of the medium was replaced with fresh neuron culture medium. The purity of 
cultures for neurons was > 98%, as determined by immunofluorescence staining for neuron-
specific class III β-tubulin.  
3.2.8 Magnetic-activated cell sorting (MACS) of CD4
+
 T cells  
CD4
+
 T cells were isolated with MACS isolation kits (Miltenyi). Spleens and/or lymph nodes 
were mechanically dissociated with 70 µm cell strainers to generate single cell suspension. Cells 
were pelleted by centrifugation at 1,200 rpm for 6 min. The cell pellet was resuspended in 40 µl 
of MACS buffer (PBS supplemented with 0.5% bovine serum albumin (BSA) and 2 mM EDTA, 
pH 7.2) per 10
7
 cells. 10 µl of the biotin-antibody cocktail per 10
7
 cells was added and incubated 
for 10 min at 4 °C. Then, 30 µl of MACS buffer and 20 µl of anti-biotin MicroBeads per 10
7
 
total cells were added and incubated for 15 min at 4 °C. After incubation, the cells were washed 
by adding 2 ml of MACS buffer per 107 cells and centrifuged at 1,200 rpm for 10 min. The pellet 
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was resuspended in 500 µl MACS buffer up to 10
8 
cells. LS columns were placed in the magnetic 
field of the MACS separator and rinsed with 3 ml of MACS buffer as preparation. The cell 
suspension was applied onto the column and the flow-through containing enriched CD4+ T cells 
was collected. The column was further washed 3 times with 3 ml MACS buffer and the flow 
through was collected. Enriched CD4
+
 T cells in the flow through were centrifuged at 1,200 rpm 
for 10 minutes and then the cells were resuspended in 500 µl of PBS. The purity of CD4
+
 T cells 
was 90-95% as determined by FACS staining. 
3.2.9 Transfection  of astrocytes  
Cultured astrocytes were subcultured one day before transfection. Cells were washed twice with 
2 ml PBS to remove remaining FCS. After that, cells were detached by incubating with trypsin at 
37 °C. Trypsinazation was stopped by adding fresh astrocyte culture medium. Cells were then 
pelleted by centrifugation at 1,200 rpm for 5 min. Cell pellet was resuspended with fresh culture 
medium and seeded in 6 well plates. On the day of tranfection, astrocytes were approximately 
80% confluent. Astrocytes were transfected with small interfering RNA (siRNA) targeting A20 
or STAT1 (pre-designed siRNA, Applied Biosystems) with the help of Lipofectamine 
RNAiMAX Reagent (Invitrogen) according to the manufacturer's instructions. 30 pmol RNAi 
duplex was diluted in 250 µl of Opti-MEM medium (gibco) in a 15 ml falcon tube for each well 
and 5 µl of Lipofectamine RNAiMAX Reagent was diluted in 250 µl of Opti-MEM medium in 
another 15 ml falcon tube for each well. Then the diluted RNAi duplex and Lipofectamine 
RNAiMAX Reagent was combined and mixed. The mixture was incubated at room temperature 
for 20 min. After incubation, the mixture was added to each well and incubated in a cell 
incubator. Medium containing transfection reagent was replaced with fresh astrocyte culture 
medium after 6 hours of incubation. Sixty hours posttransfection, cells were used for 
experiments.  
3.2.10 Quantitative real time-PCR (qRT-PCR) 
Isolation of mRNA from
 
the spinal cord of untreated and EAE mice was performed with an 
RNAeasy kit (Qiagen, Hilden, Germany). Isolated mRNA was transcribed into DNA with the 
SuperScript reverse transcriptase kit with oligo (dT) primers (Invitrogen) as described by the 
manufacturer. Quantitative RT-PCR for A20, IL-23, IL27, IL-17, IFN-γ, interleukin 6 (IL-6), 
GM-CSF, iNOS, TNF, chemokine (C-X-C motif) ligand 1 (CXCL1), chemokine (C-C motif) 
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ligand 2 (CCL2), C-X-C motif chemokine 10 (CXCL10), STAT1, and hypoxanthine 
phosphoribosyltransferase (HPRT) was performed with individual Taqman
®
 gene expression 
assay primers (Applied Biosystems, Darmstadt, Germany). Amplification was performed on the 
Lightcycler 480 system (Roche). The ratio between the respective gene and corresponding HPRT 
was calculated per mouse according to the ∆∆ cycle threshold method (Livak and Schmittgen, 
2001), and data were expressed as the increase of mRNA expression in immunized mice over 
non-immunized controls of the respective mouse strain. All primers and probes were obtained 
from Applied Biosystems. 
3.2.11 Protein isolation and Western blot 
Mouse spinal cord tissue, cultured astrocytes and neurons, and FACS-sorted microglia were 
lysed in cold RIPA cell lysis buffer on ice for 30 min. Cytoplasmic and nuclear protein was 
separated using NE-Per Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific). Lysates 
were cleared by centrifugation at 14,000 rpm for 15 min at 4 °C. The protein-containing 
supernatant was carefully transferred into a new 1.5 ml tube. Protein concentration was measured 
photometrically using the Bradford reagent (Bio-Rad) according to instructions of the 
manufacturer. After protein quantification, 5 × lane marker reducing sample buffer (Thermo 
Scientific) was added to protein and incubated at 99 °C for 5 min to denature protein. Equal 
amounts of protein were separated with 10% SDS-polyacrylamide gels, transferred to 
polyvinylidene difluoride (PVDF) membranes, and incubated with primary antibodies overnight 
at 4 °C followed by incubation with secondary antibodies. Blots were developed with an ECL 
Plus kit (GE Healthcare, Freiburg, Germany). Images were captured using the Intas Chemo Cam 
Luminescent Image Analysis system (INTAS Science Imaging Instruments) and analyzed with 
the LabImage 1D software (Kapelan Bio-Imaging Solutions, Leipzig, Germany).  
3.2.12 Immunoprecipitation  
Unstimulated and IFN-γ (10 ng/ml)-stimulated mouse astrocytes were lysed in RIPA cell lysis 
buffer as described before. 100 µl of sepharose G beads (GE Healthcare Europe GmbH, Munich, 
Germany) were added to 1 ml of cell lysate and incubated at 4 °C for 30 min on a rocker to pre-
clear the cell lysate. The beads were removed by centrifugation at 10,000 rpm for 10 min and 
supernatant was transferred to a new tube. Protein concentration of pre-cleared lysates was 
determined and adjusted to 1 µg/µl. Equal amounts of lysates were then incubated with anti-
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STAT1 and anti-A20 antibodies, respectively, at 4 °C overnight. The immunocomplex was 
captured with Sepharose G beads by overnight incubation at 4 °C. The beads were then washed 4 
times with PBS by centrifugation at 10,000 rpm for 5 sec. The pellet was resuspended in 2 × lane 
marker reducing sample buffer and incubated at 99°C for 5 min. The beads were collected by 
centrifugation and SDS-PAGE was performed with the supernatant. WB was applied to detect 
STAT1 and A20, respectively. 
3.2.13 Detection of apoptosis of astrocytes 
Apoptosis was detected with Vybrant Apoptosis Assay Kit (Invitrogen). Apoptosis was induced 
in cultured astrocytes by adding 20 or 100 ng / ml TNF, respectively, for 24 hr. Then, cells were 
harvested by trypsinization and washed with PBS (4 °C). The cell pellet was resuspended with 1 
× Annexin-binding buffer to the concentration of 1 × 106 cells / ml. Then, 5 µl of FITC annexin 
V and 1 µl of 100 µg / ml PI working solution was added to each 100 µl of cell suspension and 
incubated at room temperature for 15 min. After incubation, 400 µl of 1 × Annexin-binding 
buffer was added to the cells. Apoptosis was then measured with a FACSCanto II flow 
cytometer. 
3.2.14 Coculture of CD4
+
 T cells with astrocytes 
CD4
+
 T cells were isolated from spleens and lymph nodes of C57BL/6 mice by MACS (Miltenyi 
Biotec) as described before. Purified CD4
+
 T cells were activated for 48 h by culturing in anti-
CD3 (BD, 5 µg/ml) and anti-CD28 (eBiosciences, 2 µg/ml)-coated 96-well plates at 1-2 × 105 
cells/well in 200 µl of RPMI-1640 (Gibco) supplemented with 10% FCS (Gibco), 1% L-
glutamine (Gibco), 100 U/ml penicillin (Sigma), and 0.1 mg/ml streptomycin (Sigma). For 
coculture, 1 × 10
5
 activated T cells were inoculated in six-well plates either alone as a 
background control or on the astrocytic monolayers. After 24 h incubation, T cells were collected 
and apoptosis was detected by flow cytometry. 
3.2.15 Measurement of apoptosis of T cells 
Leukocytes isolated from spinal cord were stained with CD45-Pacific Blue, CD3-FITC, CD4-
APC, and 7-amino actinomycin D (7-AAD). Apoptosis of cocultured CD4
+
 T cells was detected 
by measuring active caspase 3 and phosphatidylserine residues exposed on the external cell 
membrane. Co-cultured CD4
+
 T cells were stained with Annexin-APC, Caspase 3-PE (Active 
Caspase-3 PE Mab Apoptosis kit, BD Bioscience), and CD4-Pacific Blue. For caspase-3 
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staining, cocultured CD4
+
 T cells were washed twice with PBS (4 °C) and then resuspended in 
BD Cytofix/Cytoperm solution at the concentration of 1 × 10
6
 cells / 0.5 ml and incubated on ice 
for 20 min. Cells were then pelleted and washed twice with BD Perm/Wash buffer at a volume of 
0.5 ml buffer per 1 × 10
6
 cells at room temperature. After washing, cells were incubated with 
Caspase 3-PE diluted in BD Perm/Wash buffer for 30 min at room temperature. Each test was 
washed with 1 ml BD Perm/Wash buffer and resuspended with 0.5 ml BD Perm/Wash buffer. 
Apoptotic CD4
+
 T cells were then analyzed by flow cytometry. 
3.2.16 Migration assay 
CD4
+
 T cells were isolated from lymph nodes of C57BL/6 mice by MACS as described before. 
Astrocytes were stimulated with or without IFN-γ (10 ng/ml) for 48 hr. Thereafter, medium was 
collected from astrocyte cultures and centrifuged at 10000 rpm for 3 min to get rid of cells and 
cell debris. The 24-well Transwell chambers (5 µm pore, Costar) were prepared by coating the 
upper part with 100 µl of 0.01% poly-l-lysine (Sigma) for 1.5 h at 37 °C. Chambers were then 
washed twice with 100 µl PBS. Conditioned astrocyte medium was added to the lower part of 
Transwell chambers and purified CD4+ T cells were placed in the upper part. After two hours of 
incubation at 37 °C, 50 µl of 0.1M EDTA was added to stop migration. Plates were shaked on a 
shaker for 10 min at room temperature. Number of CD4
+
 T cells in the lower chambers was 
counted microscopically.  
3.2.17 Immunohistochemistry 
Immunohistochemistry was performed in collaboration with Prof. Dr. Martina Deckert 
(Department of Neuropathology, University Hospital Cologne, Germany). Animals were 
anesthetized with isoflurane and then perfused intracardially with 0.9% NaCl for 
immunohistochemistry on frozen sections. For histology on paraffin sections, anesthetized mice 
were perfused with 0.9% NaCl followed by perfusion with 4% paraformaldehyde. Spinal cords 
were removed and fixed with 4% paraformaldehyde for 24 h at 4 °C. Spinal cords were 
processed and stained with hemalum & eosin, cresyl violet and luxol fast blue. For macrophage 
and neurofilament staining, spinal cords were stained with rat anti-mouse Mac-3 (BD), anti-
mouse CD3 (Serotec, Düsseldorf, Germany), and  rabbit anti-neurofilament light (NF-L, 
Chemicon, Limburg, Germany) in an ABC protocol with 3,3’-diaminobenzidine (Sigma) and 
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H2O2 (Merck). Images were acquired with a Zeiss Axiophot using Zeiss Axioplan objective 
lenses, a Zeiss Axicam camera and Zeiss Axiovision software (Zeiss, Oberkochen, Germany). 
3.2.18 Statistics 
To test for statistical differences, the two-tailed Student’s t-test was used. P values < 0.05 were 
accepted as significant. All experiments were performed at least twice.   
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4. Results 
4.1 Function of astrocytic A20 in EAE 
4.1.1 Upregulation of A20 in the spinal cord during EAE  
To explore a possible role of A20 in EAE, C57BL/6 mice were actively immunized with myelin 
oligodendrocyte glycoprotein (MOG)35-55 peptide and A20 mRNA expression was analyzed by 
quantitative real-time PCR in spinal cord at day 15 and day 22 post immunization (p.i.), 
respectively. A20 mRNA expression was significantly upregulated in the spinal cord at both day 
15 and day 22 p.i. (Fig. 10) suggesting a possible function of CNS-derived A20 during EAE. 
 
Figure 10. Upregulation of A20 in the spinal cord during EAE. mRNA transcription of A20 in the spinal cord 
was evaluated by quantitative RT-PCR in untreated and MOG35-55-immunized C57BL/6 mice at day 15 and 22 p.i (n 
= 3). Data are expressed as the increase of A20 mRNA of immunized over unimmunized mice normalized to HPRT 
(mean + SEM * p < 0.05) 
 
4.1.2 Aggravated EAE of Nestin-Cre A20
fl/fl
 mice  
To study the contribution of A20 derived from CNS-resident cells to EAE, we generated Nestin-
Cre A20
fl/fl
 mice, in which A20 was specifically deleted in all neuroectodermal cells including 
astrocytes, neurons, and oligodendrocytes (Graus-Porta et al., 2001). Spinal cord was isolated 
from Nestin-Cre A20
fl/fl
 mice and control littermates and then Western blot (WB) was performed 
with spinal cord samples to confirm A20 deletion. WB analysis revealed that A20 expression 
was deleted in spinal cord of Nestin-Cre A20
fl/fl
 mice (Fig. 11A). In addition, deletion of A20 in 
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spinal cord of Nestin-Cre A20
fl/fl
 mice was also confirmed by quantitative real-time PCR (Fig. 
11B). To study the susceptibility of Nestin-Cre A20
fl/fl
 mice to EAE, Nestin-Cre A20
fl/fl
 mice and 
control mice were actively immunized with MOG35-55 peptide. Nestin-Cre A20
fl/fl mice displayed 
significantly stronger EAE clinical symptoms as compared to the control A20
fl/fl
 mice (Fig. 11C). 
The genotoxicity of Nestin-Cre transgene might also contributed to the increased susceptibility 
of Nestin-Cre A20
fl/fl
 mice to EAE. To rule out this possibility, EAE was induced in Nestin-Cre 
A20
wt/wt
 mice and A20
wt/wt
 mice. Nestin-Cre A20
wt/wt
 mice developed the same course of disease 
as A20wt/wt mice (Fig. 11D), showing that the aggravated EAE of Nestin-Cre A20fl/fl mice cannot 
be attributed to the Nestin-Cre transgene. 
 
Figure 11. Nestin-Cre A20
fl/fl 
mice developed more severe EAE as compared with control mice. (A) WB 
analysis for A20 in the spinal cord of Nestin-Cre A20
fl/fl
 and A20
fl/fl
 control mice. (B) RT-PCR analysis for A20 
mRNA expression in the spinal cord of Nestin-Cre A20
fl/fl
 and A20
fl/fl
 control mice (n = 3 for both groups). Data 
show the mean + SEM. (C) Clinical scores of EAE in Nestin-Cre A20
fl/fl 
(n = 7) and A20
fl/fl 
(n = 8) mice induced by 
MOG35-55-immunization. Data show the mean clinical scores + SEM (* p < 0.05). (D) Clinical scores of EAE in 
Nestin-Cre A20
wt/wt
 (n = 12) and A20
wt/wt
 (n = 11) mice induced by MOG35-55-immunization. Data show the mean 
clinical scores + SEM.  
 
4.1.3 Enhanced inflammation in the spinal cord of Nestin-Cre A20
fl/fl
 mice  
A20
fl/fl
 and Nestin-cre A20
fl/fl
 mice developed EAE characterized by inflammation of the spinal 
cord, which was, however, more prominent and widespread in Nestin-Cre A20
fl/fl
 mice (Fig. 
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12A). While in A20
fl/fl
 mice inflammation was mainly confined to the dorsal columns of the 
spinal cord, leukocytes had also infiltrated the anterior and posterior spinocerebellar tracts, even 
reaching the spino-olivary fibers, the olivospinal, and the vestibulospinal tracts in Nestin-Cre 
A20
fl/fl
 mice. In addition, demyelination and axonal damage were also more prominent in Nestin-
Cre A20
fl/fl 
mice as compared to A20
fl/fl
 mice. Whereas in A20
fl/fl
 mice EAE regressed beyond 
day 15 p.i. with only small residual inflammatory infiltrates, Nestin-Cre A20
fl/fl
 mice still had 
prominent autoimmune inflammation with accompanying widespread demyelination and axonal 
damage in the spinal cord (Fig. 12A).  
At day 15 p.i., a higher percentage of CD4
+
 T cells infiltrating the spinal cord was 
detected in Nestin-Cre A20
fl/fl
 mice as compared to A20
fl/fl
 mice (Fig. 12B). At day 22 p.i., the 
time point when Nestin-Cre A20
fl/fl
 mice showed significantly more severe clinical symptoms 
than control mice, both the percentage and number of invading CD4
+
 T cells was significantly 
increased in the spinal cord of Nestin-Cre A20fl/fl mice (Fig. 12B, C). The percentage and 
number of infiltrating CD4
+
 T cells did not differ between unimmunized animals of the two 
mouse strains (day 0) showing that Nestin-Cre A20
fl/fl 
mice did not develop spontaneous 
inflammation in the CNS (Fig. 12B, C). Correspondingly, at day 22 p.i., higher levels of 
proinflammatory IFN-γ, IL-17, TNF, GM-CSF, IL-6, CXCL1, CCL2, and CXCL10 mRNA were 
detected in the spinal cord of Nestin-Cre A20fl/fl mice (Fig. 12D). Noteworthy, in the CNS, 
astrocytes are a major inducible source of the chemokines CXCL1, CCL2, and CXCL10 (Le et 
al., 2010; Miljkovic et al., 2011) and chemokine production by astrocytes is critical for EAE 
pathogenesis, implying that the aggravated EAE in Nestin-Cre A20
fl/fl
 mice might be attributed 
to the deletion of A20 in astrocytes. 
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Figure 12. Exacerbated inflammation in the spinal cord of Nestin-Cre A20
fl/fl 
mice. (A) At day 15 p.i., a 
prominent inflammatory infiltrate is associated with edema and focal loss of myelin in the posterior dorsal 
spinocerebellar tract of an A20
fl/fl 
mouse. In a Nestin-Cre A20
fl/fl
 mouse, highly cellular infiltrates are disseminated 
throughout the posterior columns bilaterally, also extending into the posterior dorsal spinocerebellar tracts. 
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Accordingly, edema and loss of myelin are much more pronounced as compared to A20
fl/fl 
mice. At day 22 p.i., 
inflammation has regressed in an A20fl/fl mouse, in which only a perivascular lymphocytic infiltrate slightly 
extending into the neighbored parenchyma of the posterior column of the spinal cord is detectable. In contrast, 
inflammation and demyelination are progressive in a Nestin-Cre A20
fl/fl
 mouse. The white matter of the posterior 
columns and the posterior as well as the anterior spinocerebellar tracts are heavily infiltrated by leukcoytes. In 
addition to pronounced edema, myelophages are present indicating ongoing demyelination. Cresyl violet and luxol 
fast blue staining. Original magnification ×200. (B) CD4+ and CD8+ T cells infiltrating the spinal cords of MOG35-
55-immunized Nestin-Cre A20
fl/fl 
and A20
fl/fl
  mice was analyzed by flow cytometry at day 0, 15 and 22 p.i. 
Representative dot plots are shown. (C) Absolute number of CD4
+
 and CD8
+
 T cells in the spinal cords of MOG35-55-
immunized Nestin-Cre A20
fl/fl 
and A20
fl/fl 
mice at day 0 (n = 4 for both groups) and 22 p.i. (n = 6 for both groups) 
(mean + SEM * p < 0.05). (D) RT-PCR analysis of relative expression of inflammatory genes as indicated in spinal 
cords of MOG35-55-immunized Nestin-Cre A20
fl/fl 
and A20
fl/fl 
mice (n = 3 for both groups) at day 22 p.i. Data 
represent the mean + SEM as relative increase over unimmunized mice 
 
4.1.4 A20-deficiency in astrocytes aggravates EAE 
In order to precisely elucidate the function of A20 derived from astrocytes in EAE, we generated 
GFAP-Cre A20
fl/fl 
mice, which lacked A20 electively in astrocytes, and challenged them with 
EAE. Primary astrocytes and neurons were isolated from new born mice or E18.5 fetus, 
respectively, and cultured in vitro. Microglia was harvested from astrocyte cultures by FACS 
sorting. WB was performed with astrocyte, neuron, and microglia samples to confirm A20 
deletion. WB analysis showed that efficient A20 deletion was achieved in astrocytes (Fig. 13A), 
and no obvious A20 deletion was detected in microglia and neurons of GFAP-Cre A20
fl/fl 
mice 
(Fig. 13B). EAE was induced in GFAP-Cre A20
fl/fl
 mice by active immunization with MOG35-55 
peptide.  Similar to Nestin-Cre A20fl/fl mice, GFAP-Cre A20fl/fl mice showed significantly more 
severe clinical symptoms than control mice (Fig. 13C), demonstrating that A20 in astrocytes is 
important for the amelioration of EAE. EAE symptoms of GFAP-Cre A20
wt/wt
 mice were similar 
to that of A20
wt/wt
 mice (Fig. 13D), showing that the more severe EAE of GFAP-Cre A20
fl/fl
 
mice was not due to the GFAP-Cre transgene. Histology showed that GFAP-Cre A20
fl/fl
 mice 
displayed more pronounced demyelination in the spinal cord than control mice at day 15 p.i. 
(Fig. 13E). Up to day 22 p.i., demyelination and axonal damage had regressed in A20
fl/fl
 mice, 
but persisted in GFAP-Cre A20
fl/fl
 mice.  
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Figure 13. EAE was aggravated in GFAP-Cre A20
fl/fl
 mice. (A) WB analysis for A20 expression in cultured 
astrocytes isolated from GFAP-Cre A20
fl/fl
 and A20
fl/fl
 control mice (left). The right panel shows the relative 
quantification of A20 normalized to GAPDH. Data show the mean + SEM. (B) WB analysis for A20 expression in 
FACS-sorted microglia and cultured neurons from GFAP-Cre A20
fl/fl
 and A20
fl/fl
 mice. (C) Clinical scores of EAE 
in GFAP-Cre A20
fl/fl 
(n = 10) and A20
fl/fl 
(n = 15) mice induced by MOG35-55-immunization. Data show the mean 
clinical scores + SEM (* p < 0.05). (D) Clinical scores of EAE in GFAP-Cre A20wt/wt (n = 5) and A20wt/wt (n = 5) 
mice induced by MOG35-55-immunization. Data show the mean clinical scores + SEM. (E) At day 15 p.i., a GFAP-
Cre A20
fl/fl 
mouse shows widespread inflammation, edema, and focal loss of myelin in the posterior colums and the 
spinocerebellar tracts. In contrast, inflammation and demyelination are much milder in an A20
fl/fl
 mouse. At day 22 
p.i., inflammation and demyelination are still active in the posterior columns of a GFAP-Cre A20
fl/fl
 mouse, whereas 
they have declined in an A20
fl/fl
 mouse. Cresyl violet and luxol fast blue staining. Original magnification ×200 
 
4.1.5 A20 deletion in neurons does not aggravate EAE 
Although we did not observe A20 deletion in cultured neurons of GFAP-Cre A20
fl/fl 
mice, it has 
been shown that low levels of gene deletion can occur in neurons of GFAP-Cre expressing mice. 
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To consolidate the contention that EAE development was not influenced by A20 deletion in 
neurons, we generated Synapsin-Cre A20
fl/fl
 mice, in which A20 was efficiently and specifically 
deleted in neurons (Fig. 14A). Synapsin-Cre A20fl/fl mice developed comparable clinical 
symptoms as A20
fl/fl 
mice (Fig. 14B) illustrating that neuronal A20 deletion does not cause 
aggravation of EAE. 
 
Figure 14. EAE was not aggravated in Synapsin-Cre A20
fl/fl
 mice. (A) WB analysis for A20 expression in 
cultured neurons from neuron-restricted A20 deficient (Synapsin-Cre A20
fl/fl
) and control (A20
fl/fl
) mice. The right 
panel shows the relative quantification of A20 normalized to GAPDH. Data show the mean + SEM. (B) Clinical 
scores of EAE in Synapsin-Cre A20fl/fl (n = 8) and A20fl/fl (n = 6) mice induced by MOG35-55-immunization. Data 
show the mean clinical scores + SEM 
 
4.1.6 Increased infiltration of inflammatory cells in the spinal cord of GFAP-Cre A20
fl/fl
 
mice 
In accordance with the histopathological results, the number of leukocytes infiltrating the spinal 
cord of GFAP-Cre A20
fl/fl
 was increased with a higher percentage of CD4
+
 T lymphocytes at 
both early (day 15 p.i.) and late (day 22 p.i) stages of EAE (Fig. 15A, B). The number of 
infiltrating leukocytes and the percentage of infiltrating CD4
+
 T cells did not differ between 
unimmunized animals of both mouse strains (day 0) showing that GFAP-Cre A20fl/fl mice did not 
develop spontaneous inflammation in the CNS (Fig. 15A, B). In addition to CD4
+
 T cells, 
absolute numbers of infiltrating CD8
+
 T cells, Ly6C
hi
 CD11b
+
 inflammatory monocytes, and 
F4/80
+
 CD68
+
 macrophages were also significantly increased in the spinal cord of GFAP-Cre 
A20
fl/fl
 mice at both day 15 and 22 p.i. (Fig. 15C).  
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Figure 15. Increased immune cell infiltration in the spinal cords of GFAP-Cre A20
fl/fl 
mice during EAE. (A) 
Absolute number of infiltrating CD45
+
 cells in the spinal cords of unimmunized or MOG35-55-immunized GFAP-Cre 
A20
fl/fl 
and A20
fl/fl 
mice (n = 6 for both groups) (mean + SEM * p < 0.05). (B) Percentage of infiltrating CD4
+
 T cells 
in the spinal cords of MOG35-55-immunized GFAP-Cre A20
fl/fl 
and A20
fl/fl 
mice was analyzed by flow cytometry. 
Representative dot plots are shown. (C) Absolute number of infiltrating immune cells in the spinal cords of GFAP-
Cre A20
fl/fl 
and A20
fl/fl 
mice at day 0 (n = 6 for both groups), 15 (n = 6 for GFAP-Cre A20
fl/fl
 group; n = 5 for A20
fl/fl 
group), and 22 (n = 6 for both groups) p.i. (mean + SEM * p < 0.05).   
 
4.1.7 GM-CSF, IL-17, and IFN-γ-producing T cells are increased in the spinal cord of 
GFAP-Cre A20
fl/fl
 mice 
Given that GM-CSF, IL-17, and IFN-γ-producing T cells can all induce EAE (Brustle et al., 
2012; Codarri et al., 2011; Domingues et al., 2010) while regulatory Foxp3
+ 
CD4
+
 T cells 
suppress the disease (Anderton and Liblau, 2008; McGeachy et al., 2005), we studied these 
subpopulations of invading CD4+ T cells. At both days 15 and 22 p.i., numbers of activated 
CD69
+
 CD4
+
 T cells were increased in the spinal cord of GFAP-Cre A20
fl/fl
 mice (Fig. 16A). In 
contrast, the percentage of Foxp3
+
 regulatory CD4
+
 T cells was significantly decreased in the 
spinal cord of GFAP-Cre A20
fl/fl
 mice at day 22 p.i. (Fig. 16B). Flow cytometry showed that 
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only the percentage of IL-17 but not of IFN-γ and GM-CSF producing CD4
+
 T cells was 
increased in GFAP-Cre A20
fl/fl
 mice. However, the total number of all three T cell populations 
was significantly increased in the spinal cord of GFAP-Cre A20fl/fl mice as compared to A20fl/fl 
mice (Fig. 16C) explaining the more severe EAE in GFAP-Cre A20
fl/fl
 mice. 
 
Figure 16. Increased activated T cells in the spinal cords of GFAP-Cre A20
fl/fl 
mice during EAE. (A) Absolute 
number of CD69
+
 CD4
+
 T cells was calculated based on flow cytometry results at day 15 (n = 6 for GFAP-Cre 
A20
fl/fl
 group; n = 5 for A20
fl/fl 
group) and 22 (n = 6 for both groups) p.i. (mean + SEM * p < 0.05). (B) 
Representative dot plots show Foxp3
+
 CD4
+ 
T cells in the spinal cords of MOG35-55-immunized GFAP-Cre A20
fl/fl 
and A20
fl/fl 
mice at day 22 p.i. (C) The relative (left panel) and absolute (right panel) number of IL-17
+
 CD4
+
, IFN-γ
+
 
CD4
+
, and GM-CSF
+
 CD4
+
 T cells in the spinal cords of MOG35-55-immunized GFAP-Cre A20
fl/fl 
and A20
fl/fl 
mice 
(n = 6 for both groups) at day 22 p.i. was analyzed by flow cytometry (mean + SEM * p < 0.05) 
 
4.1.8 Increased proinflammatory gene transcription in the spinal cord of GFAP-Cre A20
fl/fl
 
mice 
To examine the impact of astrocytic A20 on the expression of proinflammatory genes in the 
spinal cord during EAE, quantitative real-time PCR for cytokine and chemokine mRNA 
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transcripts was performed on spinal cord tissue at days 15 and 22 p.i., respectively. Already at 
day 15 p.i., GFAP-Cre A20
fl/fl
 mice had significantly increased transcription of IFN-γ, TNF, IL-
6, CXCL1, and CCL2 mRNA (Fig. 17A-H). At day 22 p.i., TNF and CXCL10 mRNA was still 
significantly elevated in GFAP-Cre A20
fl/fl
 mice as compared to control mice (Fig. 17A-H). The 
significantly higher levels of chemoattractant IL-6, CXCL1, CCL2, and CXCL10 mRNA in 
spinal cords of GFAP-Cre A20
fl/fl
 mice during EAE implied that the more severe EAE in GFAP-
Cre A20
fl/fl
 mice might be attributed to the enhanced chemokine production by A20-deficient 
astrocytes. 
 
                      
Figure 17. Increased pro-inflammatory gene expression in the spinal cords of GFAP-Cre A20
fl/fl
 mice. (A-H) 
Expression of (A) IFN-γ, (B)  IL-17, (C)  TNF, (D)  GM-CSF, (E)  IL-6, (F) CXCL1, (G)  CCL2, and (H)  CXCL10 
mRNA was determined by quantitative RT-PCR in GFAP-Cre A20
fl/fl
 and A20
fl/fl
 mice at days 15 and 22 p.i. Spinal 
cords of three mice per group were analyzed. Data represent the mean + SEM as relative increase over unimmunized 
mice (* p < 0.05) 
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4.1.9 Enhanced production of chemokines by A20-deficient astrocytes in vitro 
Astrocytes are a major producer of proinflammatory cytokines and chemokines in the CNS 
during EAE upon stimulation with TNF, IFN-γ, and IL-17 (Dong and Benveniste, 2001; Zepp et 
al., 2011). Therefore, we studied the regulation of chemokine production by A20 in cytokine-
stimulated astrocytes in vitro. A20-deficient astrocytes expressed more CXCL10, CCL2, and 
CXCL1 mRNA in response to IL-17, IFN-γ, TNF, IL-17 + TNF, and IFN-γ + TNF, respectively 
(Fig. 18A-D). In addition, A20-deficient astrocytes expressed more IL-6 mRNA in response to 
IFN-γ and IFN-γ + TNF, respectively (Fig. 18C).  
Although GM-CSF has been shown to play a pivotal role in EAE (Petermann and Korn, 
2011), the function of GM-CSF on astrocytes is largely unknown. A20-sufficient astrocytes 
expressed only low levels of CXCL10, CCL2, CXCL1, and IL-6 mRNA upon GM-CSF 
stimulation, but the level of all these mRNAs increased dramatically in the absence of A20 (Fig. 
18E). These data suggest that GM-CSF contributes to the aggravated EAE in GFAP-Cre A20fl/fl 
mice at least partially by inducing chemokine production in astrocytes. Taken together, these 
results show that in response to proinflammatory cytokines produced by encephalitogenic T 
cells, A20-deficient astrocytes in GFAP-Cre A20
fl/fl
 mice exhibited an elevated production of 
chemoattractant cytokines and chemokines, which was also observed in vivo (Fig. 17) and 
paralleled by increased recruitment of encephalitogenic CD4+ T cells and more severe EAE. 
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Figure 18. Increased in vitro pro-inflammatory gene transcription in A20-deficient astrocytes. (A-D) RT-PCR 
analysis of (A) CXCL10, (B) CCL2, (C) IL-6, and (D) CXCL1 in control (n = 2) and A20-deficient (n = 2) 
astrocytes left untreated or treated with IL-17 (50 ng/ml), IFN-γ (10 ng/ml) or TNF (10 ng/ml) alone or with IL-17 + 
TNF or IFN-γ + TNF for 16 hr. Data represent the mean + SEM as relative increase over untreated control samples. 
(E) RT-PCR analysis of CXCL10, CCL2, IL-6 and CXCL1 in control (n = 3) and A20-deficient (n = 3) astrocytes 
stimulated with GM-CSF (20 ng/ml) for 16 hr. Data represent the mean + SEM as relative increase over untreated 
control samples (* p < 0.05) 
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4.1.10 A20-deletion does increase apoptosis of astrocytes 
Since (i) astrocyte loss is found in the center of the demyelinated lesions in patients suffering 
from acute MS (Ozawa et al., 1994), (ii) astrocyte survival is important for the control of EAE 
(Haroon et al., 2011; Voskuhl et al., 2009), and (iii) A20 can regulate apoptosis (Lee et al., 2000; 
Tavares et al., 2010; Vucic et al., 2011), we investigated whether the exacerbated EAE in GFAP-
Cre A20
fl/fl
 mice was due to enhanced astrocyte apoptosis. A20-deficient astrocytes stimulated in 
vitro with increasing concentrations of TNF did not undergo enhanced apoptosis as compared to 
A20-sufficient astrocytes (Fig. 19) suggesting that A20 does not critically regulate apoptosis of 
astrocytes in EAE. Therefore, the exacerbated EAE in GFAP-Cre A20
fl/fl
 mice should be 
attributed to the enhanced chemokine production by astrocytes. 
 
Figure 19. Normal apoptosis of A20-deficient and -sufficient astrocytes after TNF stimulation. Astrocytes 
isolated from GFAP-Cre A20
fl/fl
 and A20
fl/fl
 mice were treated with 20 or 100 ng/ml TNF, respectively, for 24 hr. 
Apoptosis was detected by PI and Annexin staining 
 
4.1.11 A20 negatively regulates NF-κB, MAP kinase, and STAT1 pathways induced by 
fingerprint cytokines of autoreactive T cells 
To understand how A20 suppresses chemokine production, we studied signaling pathways 
induced by TNF, IL-17, IFN-γ, and GM-CSF. Consistent with previous reports of A20 as a 
negative regulator of the canonical NF-κB pathway (Skaug et al., 2011) and that NF-κB pathway 
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is activated in response to TNF, IL-17, and GM-CSF (Bulek et al., 2011; Meads et al., 2010), 
enhanced phosphorylation of IκBα was detected in A20-deficient astrocytes in response to all 
three cytokines (Fig. 20A-C). In addition, A20 deficiency also enhanced p38 and JNK 
phosphorylation upon stimulation with TNF, IL-17, and GM-CSF (Fig. 20A-C).  
A20-deficient astrocytes produced significantly more chemokines in response to IFN-γ 
(Fig. 18) implying that A20 might also negatively regulate IFN-γ-induced signaling. Although 
phosphorylation of STAT1 at tyrosine 701 was only slightly increased in the absence of A20, 
phosphorylation of serine 727 was dramatically increased in A20-deficient astrocytes (Fig. 20D). 
An analysis of cytosolic and nuclear extracts of IFN-γ-stimulated astrocytes showed that the 
increased phosphorylation of serine 727 occurred in both cytoplasm and nucleus (Fig. 20E). 
Strikingly, the protein level of STAT1 was also increased in A20-deficient astrocytes (Fig. 20D, 
E).  
 
Figure 20. A20 negatively regulates multiple signaling pathways in astrocytes. (A-D) Western blot of whole cell 
lysates stimulated for the indicated time points with (A) TNF (10 ng/ml), (B) IL-17 (50 ng/ml), (C) GM-CSF (20 
ng/ml), and (D)  IFN-γ (10 ng/ml). (E) Western blot of cytoplasmic and nuclear extracts after stimulation with IFN-
γ (10 ng/ml) for the indicated time points 
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4.1.12 A20 inhibits STAT1 expression in astrocytes 
To rule out the possibility that STAT1 protein level was increased due to a genotoxic effect of 
the GFAP-Cre transgene, we studied the correlation between STAT1 expression and A20 
expression by RNA interference (RNAi). Compared with control siRNA, A20 knockdown 
significantly enhanced expression of STAT1 (Fig. 21) confirming that A20 negatively regulates 
the protein level of STAT1. 
 
 
Figure 21. STAT1 expression was upregulated in astrocytes after A20 siRNA treatment. (A) Astrocytes 
derived from C57BL/6 mice were transfected with siRNA targeting A20 or nonsense siRNA. Sixty hours later, WB 
analysis was performed on total cell lysates for A20, STAT1 and GAPDH. (B) Relative quantification of A20 
normalized to GAPDH. Data show the mean + SEM. (C) Relative quantification of STAT1 normalized to GAPDH. 
Data show the mean + SEM 
 
4.1.13 A20 inhibits IFN-γ-induced STAT1-dependent chemokine production and T cell 
migration 
The increased STAT1 protein levels of A20-deficient astrocytes were likely caused by an 
elevated STAT1 mRNA production as compared to A20-sufficient astrocytes (Fig. 22A). 
Interestingly, inhibition of NF-κB abolished the upregulated STAT1 mRNA production of A20-
deficient astrocytes indicating that A20 indirectly modulated STAT1 function via controlling 
NF-κB activation (Fig. 22B). Knockdown of STAT1 by siRNA (Fig. 22C) revealed that in IFN-
γ-stimulated astrocytes the increased CXCL10 and CCL2 mRNA production was largely 
dependent on STAT1 (Fig. 22D).  
Since A20 strongly suppressed IFN-γ-induced STAT1-dependent chemokine production 
of astrocytes, we next studied the impact of A20 on astrocyte-induced T cell migration. In 
accordance with the in vitro chemokine production data, IFN-γ-conditioned medium of A20-
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deficient astrocytes induced recruitment of an increased number of CD4
+
 T cells as demonstrated 
by an in vitro CD4
+
 T cell migration assay (Fig. 22E). 
 
Figure 22. A20 negatively regulates STAT1 expression on the transcriptional level in a NF-κB-dependent 
fashion. (A) RT-PCR analysis of STAT1 mRNA expression in cultured astrocytes derived from GFAP-Cre A20
fl/fl
 
and A20
fl/fl
 mice (left). The right panel shows the relative quantification of STAT1 normalized to HPRT (mean + 
SEM * p < 0.05). (B) RT-PCR analysis for the STAT1 mRNA expression after IKK inhibitor (1 µM) treatment for 
48 hr (mean + SEM * p < 0.05). (C) Astrocytes derived from GFAP-Cre A20
fl/fl
 and A20
fl/fl
 mice were transfected 
with siRNA targeting STAT1 or nonsense (Ns) siRNA. Sixty hours later, WB analysis was performed on total cell 
lysates for STAT1 and GAPDH. (D) Sixty hours after siRNA transfection, astrocytes were left untreated or treated 
with IFN-γ (10 ng/ml) for 16 hr. CXCL10 and CCL2 mRNA levels were determined by RT-PCR. Data represent the 
mean + SEM as relative increase over untreated control samples (* p < 0.05). (E) Purified CD4
+
 T cells were placed 
into the upper part of transwell chambers with untreated or IFN-γ-conditioned medium (48 hr stimulation) of 
cultured astrocytes isolated from GFAP-Cre A20
fl/fl
 and A20
fl/fl
 mice in the lower part. After two hours of 
incubation, migrated T cells in the lower chambers were counted. T cell migration was calculated as relative 
increase over untreated controls (mean + SEM * p < 0.05) 
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Based on these findings, we conclude that A20 prevents the hyperactivation of multiple signaling 
pathways in astrocytes in response to cytokines produced by autoimmune T cells. Therefore, 
A20 suppresses the production of chemoattractant cytokines and chemokines by astrocytes, 
resulting in diminished recruitment of inflammatory leukocytes to the CNS and amelioration of 
EAE. 
 
 
 
4.2 Function of astrocytic FasL in EAE 
In order to determine whether FasL+ astrocytes are inducers of CD4+ T-cell apoptosis in EAE, 
we generated GFAP-Cre FasL
fl/fl
 mice that are deficient of FasL selectively in astrocytes. We 
show in the present study that astrocytic FasL is crucial to terminate the autoimmune T-cell 
response in the CNS, which allows clinical recovery from EAE. 
4.2.1 Selective deletion of FasL in astrocytes of GFAP-Cre FasL
fl/fl
 mice 
We generated GFAP-Cre FasLfl/fl mice with selective FasL deletion in the CNS (Fig. 23A). 
Further PCR analysis of cultivated cells showed FasL deletion in astrocytes and to a minor extent 
in neurons (Fig. 23B). In contrast, microglia of GFAP-Cre FasL
fl/fl
 as well as astrocytes, neurons, 
and microglia of FasL
fl/fl
 control mice did not show deletion of FasL (Fig. 23B). To confirm 
astrocytic FasL deletion at the protein level, cell surface expression of FasL protein was analysed 
by flow cytometry from cultivated astrocytes of GFAP-Cre FasLfl/fl and FasLfl/fl mice. As shown 
in Fig. 23C, FasL expression was reduced on the surface of astrocytes from GFAP-Cre FasL
fl/fl
 
as compared with those from FasL
fl/fl
 mice. Both GFAP-Cre FasL
fl/fl
 mice and FasL
fl/fl
 (control) 
mice were born in a normal Mendelian ratio and reached adulthood without any CNS defects.  
Collectively, these findings show that astrocyte-specific deletion of FasL was achieved in 
our newly generated GFAP-Cre FasLfl/fl mice, which did not show abnormalities under 
physiological conditions, thereby providing a useful tool for studying the function of astrocyte-
specific FasL in experimentally induced models of CNS disorders. 
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Figure 23. Organ and cell-type-specific deletion of FasL in GFAP-Cre FasL
fl/fl 
mice. (A) Deletion of FasL in 
various organs of non-immunized GFAP-Cre FasL
fl/fl
 and FasL
fl/fl
 mice was analysed by PCR. The FasL∆ product 
has a size of 500 bp. Representative data from one of two experiments with three mice each are shown. (B) Deletion 
of FasL from cultivated and FACS-sorted astrocytes, microglia, and cultivated neurons of GFAP-Cre FasL
fl/fl
 (lanes 
labelled 1) and FasL
fl/fl
 (lanes labelled 2) mice. Total brain (positive control) was from a GFAP-Cre FasL
fl/fl
 mouse. 
(C) Cell surface expression of the FasL protein (right) was analysed by flow cytometry from cultivated astrocytes of 
GFAP-Cre FasL
fl/fl
 and FasL
fl/fl
 mice. Staining with control mouse antibody is shown (left). Representative data 
from one of two experiments are shown and the mean fluorescence intensity of FasL expression is given in each 
histogram.  
4.2.2 Aggravated EAE of GFAP-Cre FasL
fl/fl
 mice with increased inflammation and 
demyelination 
To gain insight into the astrocyte-specific function of FasL in the pathogenesis of EAE, we 
actively immunized GFAP-Cre FasLfl/fl mice and control mice with MOG35-55 peptide emulsified 
in complete Freund’s adjuvant (CFA) and assessed clinical disease activity daily. Both GFAP-
Cre FasL
fl/fl
 mice and FasL
fl/fl
 control mice developed EAE starting at around day 9 p.i. and 
reaching peak disease at day 15 p.i.; over this period of time they developed similar clinical 
symptoms (Fig. 24A). However, beyond the maximum of disease, i.e. day 15 p.i., FasL
fl/fl
 mice 
recovered gradually while EAE progressed in GFAP-Cre FasLfl/fl mice indicating a significantly 
more severe course of EAE in the later group of mice (Fig. 24A). Already at day 15 p.i., 
inflammation of GFAP-Cre FasL
fl/fl
 mice was more severe and more widespread as compared 
with that in control animals, leading to more severe demyelination. While inflammatory foci 
consisting of CD3
+
 T cells and macrophages were confined to the dorsal columns of the spinal 
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cord in FasL
fl/fl
 mice, they also infiltrated the spinocerebellar tracts in GFAP-Cre FasL
fl/fl
 mice. 
Differences between the two mouse strains were more prominent at day 22 p.i. as compared with 
those at day 15 p.i. Inflammation and demyelination were mild in FasLfl/fl mice (Fig. 24B, D) as 
compared with that in GFAP-Cre FasL
fl/fl
 mice, with widespread inflammatory foci consisting of 
CD3
+
 T cells and Mac3
+
 macrophages (Fig. 24C, E). In GFAP-Cre FasL
fl/fl
 mice, demyelination 
was prominent in the posterior columns as well as in spinocerebellar tracts (Fig. 24C), which 
also showed evidence of a disturbed axonal transport as evidenced by axonal bulbs. 
Inflammation was also prominent in the dorsal horn of the spinal cord, where many infiltrates 
resided (Fig. 24E).    
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Figure 24. Aggravated EAE with increased demyelination and inflammation in GFAP-Cre FasL
fl/fl
 mice. (A) 
Clinical symptoms of GFAP-Cre FasL
fl/fl
 and FasL
fl/fl
 mice were scored daily after immunization with MOG35-55 
peptide in CFA, and data are displayed as the mean + SEM of 8-10 mice per group, from one experiment 
representative of four performed. * p < 0.05, ** p < 0.01, t-tests. (B) Lack of ongoing demyelination in the posterior 
column of the spinal cord in a FasL
fl/fl
 mouse, although myelin sheaths are reduced. Inflammatory infiltrates are 
confined to the leptomeninges (arrows), but do not infiltrate the spinal cord parenchyma. Cresyl violet - luxol fast 
blue staining. (C) Severe inflammation with leptomeningeal and spinal cord parenchymal infiltrates (arrows) with 
pronounced demyelination (*) in the posterior column of the spinal cord in a GFAP-Cre FasL
fl/fl
 mouse. Note 
numerous myelin fragments and pronounced edema. Cresyl violet - luxol fast blue staining. (D) Some CD3
+
 T cells 
contributed to leptomeningeal infiltrates (arrowheads) and only single CD3
+
 T cells are still present in parenchyma 
of the spinal cord of a FasL
fl/fl
 mouse (small arrows). Anti-CD3 immunostaining, slight counterstaining with 
hemalum. (E) Many CD3
+
 T cells form inflammatory cuffs in the posterior colums and around blood vessels in the 
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posterior horn (large arrows) and are also scattered throughout the spinal cord (small arrows) in a GFAP-Cre FasL
fl/fl
 
mouse. Anti-CD3 immunostaining, slight counterstaining with hemalum. (B-E) Histological findings of 
representative mice (day 22 p.i.) from one of two independent experiments with three mice each are shown, bar 50 
µm.  
 
4.2.3 Increased numbers of infiltrating T cells in the spinal cord of GFAP-Cre FasL
fl/fl 
mice 
Since autoimmune T cells are the key mediator of EAE, we analysed T cells infiltrating the 
spinal cord. At day 15 p.i., flow cytometry revealed that numbers of infiltrating CD4
+
 and CD8
+
 
T cells were slightly but not significantly increased in the spinal cord of GFAP-Cre FasL
fl/fl 
mice 
as compared with those in FasL
fl/fl 
mice (Fig. 25A, B), which corresponds to the similar clinical 
scores at this time point (Fig. 24). At day 22 p.i., significantly more CD4+ and CD8+ T cells were 
detected in the spinal cord of GFAP-Cre FasL
fl/fl
 mice than in FasL
fl/fl
 mice (Fig. 25A, B; p < 
0.01 for CD4
+
 and CD8
+
 T cells). 
As GM-CSF-producing CD4
+
 T cells are essential for the induction of EAE (Codarri et 
al., 2011), we determined the percentage and number of GM-CSF-producing CD4
+
 T cells in the 
spinal cord of both mouse strains. Flow cytometry revealed that GM-CSF-producing CD4+ T 
cells accounted for approximately 15% of CD4
+
 T cells in both mouse strains; however, the 
absolute number of GM-CSF-producing CD4
+
 T cells was significantly increased in GFAP-Cre 
FasL
fl/fl
 mice as compared with those in control animals at day 22 p.i. (Fig. 25C). In addition, we 
compared the phenotypic composition of CD4
+
 T cells between the two genotypes to determine 
whether astrocyte-specific deletion of FasL influenced the activation state of infiltrating CD4+ T 
cells in EAE. At day 15 p.i., the percentage of Foxp3
-
 CD25
+
 activated CD4
+
 T cells (Fig. 25D) 
and Foxp3
+
 regulatory CD4
+
 T cells (Fig. 25E) was similar in both strains of mice, whereas at 
day 22 p.i., as compared with FasL
fl/fl
 mice, the percentage of Foxp3
-
 CD25
+
 activated CD4
+
 T 
cells was increased while the percentage of Foxp3
+
 regulatory CD4
+
 T cells was reduced in 
GFAP-Cre FasLfl/fl mice respectively (Fig. 25D, E). Intraspinal CD4+ T cells from both mouse 
strains expressed Fas, as detected by flow cytometry (Fig. 25F), and, thus, they might be 
regulated by FasL
+
 cells. At d 22 p.i., the percentage of 7-aminoactinomycin (7-AAD)
+
 CD4
+
 T 
cells was significantly reduced in GFAP-Cre FasL
fl/fl
 mice as compared with that in FasL
fl/fl
 mice 
(Fig. 25G, * p < 0.05) suggesting that elimination of infiltrating T cells by apoptosis was 
impaired in GFAP-Cre FasLfl/fl mice in late stages of EAE. Annexin V staining was not used to 
detect CD4
+
 T-cell apoptosis in vivo because previous reports showed that annexin V did not 
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selectively detect apoptotic T cells, since it also stained activated CD4
+
 T cells (Elliott et al., 
2005).  
 
 
Figure 25. Increased numbers of activated and reduced numbers of regulatory T cells in the CNS of GFAP-
Cre FasL
fl/fl
 mice. (A, B) Leukocytes were isolated from the spinal cord of GFAP-Cre FasL
fl/fl
 and FasL
fl/fl
 mice and 
numbers of (A) CD4
+
 and (B) CD8
+
 T cells were determined by flow cytometry. (C) Leukocytes isolated from the 
spinal cord were stained for extracellular CD4 and CD45 and intracellular GM-CSF. Dot plots (left) show the 
percentage of CD4
+
 CD45
+
 cells (upper left) and GM-CSF
+
 CD4
+
 cells (lower left) at day 22 p.i., as well as the 
gating strategy for CD4
+
 cells. The relative (upper right) and absolute number (lower right) of GM-CSF
+
 CD4
+
 cells 
is shown. (D, E) The percentage of (D) CD25
+
 CD4
+
 T cells and (E) Foxp3
+
 regulatory CD4
+
 T cells was analysed 
by flow cytometry. (F) Cell surface expression of Fas on CD4
+
 T cells from both GFAP-Cre FasL
fl/fl
 and FasL
fl/fl
 
mice was analysed by flow cytometry at day 15 p.i. and representative histograms are shown (right). Control 
staining was performed with hamster IgG (left). The mean fluorescence intensity is shown in each histogram. (G) 
The percentage of 7-AAD
+
 CD4
+
 T cells was determined by flow cytometry at day 22 p.i., and the mean + SD is 
shown. (A-G) Data are shown as representative dot plots as well as the mean + SD of 6-9 mice per experimental 
group from one of two independent experiments. * p < 0.05, ** p < 0.01, t-tests. 
4.2.4 Increased proinflammatory gene transcription in the spinal cord of GFAP-Cre 
FasL
fl/fl
 mice 
To examine the impact of astrocyte-specific FasL deletion on the expression of proinflammatory 
genes during EAE, quantitative real time PCR for cytokines and chemokines was performed on 
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spinal cord tissue at day 15 p.i. and day 22 p.i. of EAE respectively. At day 15 p.i., IFN-γ and IL-
27 mRNA was significantly elevated in GFAP-Cre FasL
fl/fl
 mice as compared to FasL
fl/fl
 mice 
while mRNA levels of IL-17, TNF, IL-23, and GM-CSF did not differ between the two mouse 
strains (Fig. 26). In contrast, at day 22 p.i., mRNA levels of all mediators, except for IL-23, were 
significantly upregulated in GFAP-Cre FasL
fl/fl
 mice as compared with levels in FasL
fl/fl
 mice, 
indicating an increased pro-inflammatory response in the spinal cord of GFAP-Cre FasLfl/fl mice 
at this late time point (Fig. 26). Interestingly, mRNA of IL-17, a main mediator of EAE, 
persisted at high levels in the spinal cord of GFAP-Cre FasL
fl/fl
 mice up to day 22 p.i. Taken 
together, these results show that astrocytic deletion of FasL resulted in an increased transcription 
of important pro-inflammatory genes in the spinal cord which induce and contribute to severity 
of EAE. 
 
          
Figure 26. Increased pro-inflammatory gene expression in the spinal cords of GFAP-Cre FasLfl/fl mice. (A-G) 
Expression of (A) IL-17, (B) IFN-γ, (C) TNF-α, (D) GM-CSF, (E) IL-23, (F) IL-27, and (G) iNOS mRNA was 
determined by quantitative RT-PCR in GFAP-Cre FasL
fl/fl
 and FasL
fl/fl
 mice at days 15 and 22 p.i. Spinal cords of 
three mice per group were analysed. Data represent the mean + SEM as relative increase over non-immunized mice. 
* p < 0.05, ** p < 0.01, t-tests. One of two independent experiments with three mice each is shown. 
4.2.5 Reduced apoptosis of CD4
+
 T cells in co-culture with FasL-deficient astrocytes 
Twenty-four hours after co-culture of FasLfl/fl CD4+ T cells with primary astrocytes isolated from 
the CNS of FasL
fl/fl
 or GFAP-Cre FasL
fl/fl
 mice, T cell apoptosis induced by FasL-deficient 
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astrocytes was compared to that induced by control astrocytes. In accordance with a previous 
report of Bechmann et al. (Bechmann et al., 2002), significantly lower numbers of T cells co-
cultured with FasL-deficient astrocytes underwent apoptosis as demonstrated by both annexin V 
binding and caspase-3 staining (Fig. 27). Based on these findings, we conclude that, during EAE, 
astrocytic FasL-induced apoptotic elimination of T cells in the CNS of GFAP-Cre FasL
fl/fl
 mice 
is significantly compromised as compared with that of control animals, resulting in a 
significantly enhanced disease activity. 
 
Figure 27. Astrocytes induce apoptosis of activated T cells via FasL in vitro. (A, B) After monoculture or 
coculture with astrocytes from FasL
fl/fl
 or GFAP-Cre FasL
fl/fl
 mice for 24 hours, apoptosis of T cells was detected by 
(A) caspase 3 and (B) annexin V staining. No difference was observed in the corresponding control stainings with 
isotype-matched IgG (data not shown). One of two independent experiments is shown. 
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5. Discussion 
In this study, we show that in the early stage of EAE astrocytes were deactivated by A20 to 
prevent T-cell recruitment. If A20 is not active, such as in MS patients with inactive A20 
muations, astrocytes may contribute to the initiation of CNS pathology. In the late stage of EAE, 
astrocytes are protective by inducing the apoptosis of autoreactive CD4
+
 T cells. Therefore, 
astrocytes can protect the CNS from the autoimmune CD4
+
 T cell attack by A20 and FasL 
expression.  
Role of astrocytic A20 in EAE 
The first part of study demonstrates that targeted deletion of A20 in neuroectodermal cells 
increased severity of the autoimmune demyelinating disease EAE. Consistently, previous reports 
showed that blocking NF-κB in neuroectodermal cells by deleting NEMO, IKK2, and Act1, 
respectively, ameliorated EAE  (Kang et al., 2010; van et al., 2006). Although these reports point 
to an important function of astrocytic NF-κB in EAE, direct in vivo evidence using astrocyte-
specific gene-deficient mice was still missing. Here, we extend these findings and newly show 
that A20 deletion in astrocytes, but not in neurons, caused an aggravated EAE by augmenting 
NF-κB and STAT1 activity.  
Chemokine production of astrocytes is important in the effector stage of EAE that is 
associated with clinical disease onset (Miljkovic et al., 2011; Zepp et al., 2011). After priming in 
lymph nodes, antigen-specific T cells traffic through the choroid plexus to the subarachnoid 
space (Wave 1) where they are reactivated by meningeal APCs (Engelhardt and Sorokin, 2009; 
Kebir et al., 2007; Reboldi et al., 2009). Consequently, T cells expand and produce inflammatory 
cytokines, which stimulate adjacent CNS resident cells, mainly astrocytes, to produce leukocyte-
recruiting chemokines and cytokines, leading to the further recruitment of leukocytes into the 
CNS (Wave 2). We observed that IL-17, IFN-γ, TNF, and GM-CSF, which are signature 
cytokines of encephalitogenic T cells, induced significantly higher levels of CXCL1, CXCL10, 
CCL2, and IL-6 in A20-deficient astrocytes in vitro. In line with this, increased CXCL1, 
CXCL10, CCL2, and IL-6 mRNA was also detected in spinal cords of Nestin-Cre and GFAP-
Cre A20
fl/fl
 mice, respectively, as compared to control mice, suggesting that astrocytic A20 
ameliorates EAE by inhibiting the progression of Wave 1 to Wave 2 of T cell recruitment. A20 
plays divergent roles in regulating apoptosis in different cell types (Lee et al., 2000; Tavares et 
al., 2010; Vucic et al., 2011) and astrocyte survival is critical for EAE suppression (Haroon et al., 
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2011; Voskuhl et al., 2009). Importantly, we did not obtain any evidence that A20 deficiency 
rendered astrocytes more sensitive to apoptosis. Thus, the more severe EAE of Nestin-Cre and 
GFAP-Cre A20fl/fl mice was not due to the enhanced apoptosis of astrocytes.  
TNF, IL-17, and GM-CSF are produced by Th1 cells, Th17 cells, and GM-CSF-
producing CD4
+ 
T cells, respectively, and all of them can activate the NF-κB pathway (Bulek et 
al., 2011; Meads et al., 2010), which drives chemokine and cytokine production in astrocytes 
(Bruck et al., 2012; van et al., 2006). In the absence of A20, activation of NF-κB was enhanced 
in astrocytes upon stimulation with IL-17, TNF, and GM-CSF, respectively, explaining the 
increased expression of leukocyte attracting genes in A20-deficient astrocytes. Besides, A20 also 
inhibited activation of p38 and JNK pathway illustrating that the inhibitory function of A20 was 
not restricted to NF-κB. 
We observed that IFN-γ induced a dramatic increase in chemokine production in A20-
deficient astrocytes implying that A20 might interfere with IFN-γ-mediated signaling. IFN-γ 
mediated STAT1 activation was stronger in the absence of A20 as shown by increased STAT1 
phosphorylation at serine 727, which is required for the full activation of STAT1 (Decker and 
Kovarik, 2000; Varinou et al., 2003). Interestingly, STAT1 protein was also increased in 
unstimulated and IFN-γ-stimulated A20-deficient astrocytes, which was caused by an enhanced 
NF-κB-dependent STAT1 mRNA production in the absence of A20, showing that STAT1 
signaling pathway was also negatively regulated by A20. Therefore, it is possible that NF-κB-
activating cytokines such as IL17, TNF, and GM-CSF induce increased chemokine production in 
A20-deficient astrocytes by cooperation with IFN-γ-dependent STAT1 activation. In fact, 
treatment with TNF + IFN-γ resulted in an augmented production of chemokines and cytokines 
in A20-deficient astrocytes. 
STAT1 protein levels can be regulated by K48 ubiquitin-dependent proteasomal 
degradation that is induced by the E3 ligase Smurf1 (Yuan et al., 2012). As an ubiquitin E3 
ligase, A20 is involved in the proteasomal degradation of several signaling molecules including 
RIP1 (Wertz et al., 2004). However, no direct interaction between A20 and STAT1 was detected 
by immunoprecipitation ruling out the possibility that A20 promoted the degradation of STAT1 
by K48-ubiquitination or inhibited its function by K63-deubiquitination. Instead, we observed 
higher STAT1 mRNA expression in A20-deficient astrocytes than in control cells, indicating that 
the increased STAT1 protein level in A20-deficient astrocytes should be attributed to increased 
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production but not to reduced degradation. Although numerous reports mentioned 
phosphorylation of STAT1, barely any of them elucidated STAT1 production. We showed that 
A20 negatively regulated STAT1 production indirectly by inhibiting the NF-κB signaling 
cascade that is responsible for STAT1 mRNA synthesis. Our novel observation that A20 
inhibited STAT1 at both expression and phosphorylation levels explains why IFN-γ stimulated 
A20-deficient astrocytes produced more chemokines as compared to A20-sufficient astrocytes. 
The enhanced migration of wildtype CD4
+
 T cells in response to IFN-γ conditioned medium of 
A20-deficient astrocytes also provided direct evidence that the enhanced production of 
chemoattractant molecules by A20-deficient astrocytes induced CD4
+
 T cell recruitment.  
Single nucleotide polymorphisms (SNPs) in or close to the human tumor necrosis factor, 
alpha-induced protein 3 (TNFAIP3) gene are associated with several human autoimmune 
diseases including psoriasis, rheumatoid arthritis, type 1 diabetes, and systemic lupus 
erythematosus (SLE) (Fung et al., 2009; Musone et al., 2008; Musone et al., 2011; Nair et al., 
2009). Recent genome wide association study (GWAS) identified OLIG3/TNFAIP3 as a 
susceptibility locus for MS (De Jager et al., 2009). In addition, TNFAIP3 expression was found 
to be tightly correlated with clinical features of MS (Gilli et al., 2011). Compared with healthy 
controls, a lower mRNA expression of TNFAIP3 was observed in untreated patients with MS 
and its baseline levels were lower in patients with a more malignant disease course than in 
patients with a more benign course. Accordingly, treatment of MS patients with glatiramer 
acetate reverted TNFAIP3 expression to levels displayed by healthy controls.  A recent study 
showed that SNPs in the OLIG3/TNFAIP3 gene correlated significantly with increased 
cerebrospinal fluid (CSF) levels of the chemokine CXCL13, a prognostic marker for MS (Linden 
et al., 2013). Given that our study shows that astrocytic A20 suppresses EAE by inhibiting 
chemokine production in astrocytes, it therefore provides a biological rationale for the clinical 
observation that SNPs in or close to TNFAIP3 gene influences the development of MS. Thus, 
therapeutical augmentation of A20 in astrocytes might be beneficial for the treatment of MS. 
 
Role of astrocytic FasL in EAE 
The second part of study demonstrates that elimination of infiltrating encephalitogenic T 
lymphocytes is a key mechanism for EAE resolution and that FasL
+
 astrocytes are crucial to 
induce T-cell apoptosis and elimination from the CNS in this autoimmune disease. In agreement 
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with Bechmann et al  (Bechmann et al., 2002), who demonstrated that astrocytes induced 
apoptosis of activated T cells in a FasL-dependent way in vitro, we observed that FasL
+
 
astrocytes induced apoptosis of activated Fas+ CD4+ T cells in vitro. Since astrocytes are also 
FasL
+
 in multiple sclerosis, our data suggest a similar role of astrocytes for the elimination of 
inflammatory leukocytes in this severe human autoimmune disease. 
Astrocytic FasL was protective for mice during EAE, since MOG35-55-immunized mice 
lacking astrocyte-specific FasL suffered from a clinically more severe EAE compared with their 
control littermates. The onset of clinical symptoms was similar in both GFAP-Cre FasLfl/fl and 
control FasL
fl/fl
 mice at day 9 p.i. indicating that homing of myelin-specific leucocytes was not 
regulated by astrocytic FasL expression. In addition, the clinical score of GFAP-Cre FasL
fl/fl
 and 
FasL
fl/fl
 mice increased with the same kinetics until the peak of disease in FasL
fl/fl
 mice at day 15 
p.i. In accordance, numbers of CD4
+
 T cells were not significantly increased in GFAP-Cre 
FasLfl/fl mice at day 15 p.i. However, during the clinical recovery phase of FasLfl/fl mice (day 22 
p.i.), numbers of CD4
+
 T cells were significantly increased in the spinal cord of GFAP-Cre 
FasL
fl/fl
 mice as shown by both flow cytometry and histology at day 22 p.i. The reduced number 
of CD4
+
 T cells positive for 7-AAD, which identifies late apoptotic and dead cells, illustrates the 
compromised ability of FasL-deficient astrocytes to induce apoptosis and elimination of 
infiltrating autoimmune T cells. The kinetics of disease and intraspinal CD4+ T-cell numbers 
indicate that FasL-dependent elimination of CD4
+
 T cells in EAE plays a particularly protective 
role in the recovery phase. Noteworthy, the more severe EAE of GFAP-Cre FasL
fl/fl
 mice cannot 
be attributed to the GFAP-Cre transgene, since C57BL/6 GFAP-Cre mice without a loxP-flanked 
gene develop the same course of EAE as compared to wild-type mice  (Haroon et al., 2011). 
We also observed a significantly higher number of activated CD25+ CD4+ T cells and a 
significantly reduced number of Foxp3
+
 regulatory CD4
+
 T cells in the spinal cord of GFAP-Cre 
FasL
fl/fl
 as compared with FasL
fl/fl
 mice at day 22 p.i. Lack of astrocytic FasL expression altered 
the ratio of activated CD25
+
 versus regulatory Foxp3
+
 CD4
+
 T cells in the spinal cord from 5:1 in 
FasL
fl/fl
 mice to 10:1 in GFAP-Cre FasL
fl/fl
 mice. These data suggest that astrocytic FasL 
expression predominantly contributes to elimination of activated disease-promoting CD25+ CD4+ 
T cells but not of protective regulatory Foxp3
+
 CD4
+
 T cells in order to recover from EAE and to 
achieve a restitutio ad integrum. These data are in line with previous reports illustrating that 
astrocytes induce a regulatory phenotype in autoimmune CD4
+
 T cells (Trajkovic et al., 2004), 
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which play an important protective role in EAE (Gultner et al., 2010; Tsakiri et al., 2012). In 
agreement, the number of GM-CSF-producing CD4
+
 T cells, i.e. the essential EAE-inducing 
CD4+ T-cell subset (Codarri et al., 2011), was significantly increased in the spinal cord of 
GFAP-Cre FasL
fl/fl
 mice at day 22 p.i. 
The increased number of infiltrating activated autoreactive CD4
+
 T cells in GFAP-Cre 
FasL
fl/fl
 mice was associated with an enhanced production of proinflammatory cytokines. At day 
15 p.i., IFN-γ, TNF, GM-CSF, IL-27 and iNOS but not IL17 mRNA was increased in GFAP-Cre 
FasL
fl/fl
 mice as compared with that in FasL
fl/fl
 mice. IFN-γ, TNF, and GM-CSF have been 
reported to contribute to disease progression and demyelination in EAE (Codarri et al., 2011; 
Petermann and Korn, 2011). GM-CSF and IFN-γ are mainly produced by encephalitogenic T 
cells. GM-CSF sustains neuroinflammation via myeloid cells that infiltrate the spinal cord. In 
addition to its pro-inflammatory function, IFN-γ is also a potent stimulator of IL-27 production 
by astrocytes (Fitzgerald et al., 2007), which might explain the increased production of this 
immunosuppressive and protective cytokine in the spinal cord of GFAP-Cre FasL
fl/fl
 mice at day 
15 p.i. IL-27 can suppress IL-17 production of primed Th17 cells (Fitzgerald et al., 2007), which 
might explain that GFAP-Cre FasL
fl/fl
 mice did not show elevated IL-17 mRNA expression in the 
spinal cord as compared to FasL
fl/fl
 mice. IL-17 is an important cytokine contributing to 
demyelination and progression of EAE (Komiyama et al., 2006). Comparable levels of IL-17 
mRNA transcription in GFAP-Cre FasL
fl/fl
 and FasL
fl/fl
 mice at day 15 p.i. might, therefore, 
explain similar clinical scores in the two mouse strains at this stage of disease. However at day 
22 p.i., when numbers of activated CD25
+
 and GM-CSF-producing CD4
+
 T cells were 
significantly increased and numbers of Foxp3
+
 regulatory CD4
+
 T cells decreased in GFAP-Cre 
FasLfl/fl mice, IL-17 mRNA was very prominently increased in addition to IFN-γ, TNF, GM-
CSF, and iNOS mRNA. Thus, aggravation of clinical symptoms in GFAP-Cre FasL
fl/fl
 mice 
correlated with an increased IL-17 mRNA transcription, indicating that this cytokine was 
decisive for the more severe and persisting EAE in these mice. IL-23, which drives IL-17 
polarisation of CD4
+
 T cells was not increased in the CNS of GFAP-Cre FasL
fl/fl
 mice, which fits 
to the important role of IL-23 for Th17 polarisation in lymphatic organs (Kobayashi et al., 2008).  
The second part of study illustrates that astrocytes confer protection against EAE by the FasL-
dependent apoptotic elimination of activated CD25
+
 Foxp3
-
 and GM-CSF-producing CD4
+
 T 
cells and the concomitant inhibition of proinflammatory cytokine production. Thus, 
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augmentation of astrocytic FasL may provide a favourable strategy for treatment of clinically 
active MS. 
 
Summary of the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Graphic summary of the present study.  
Collectively, in the present study, we extend the in vivo function of astrocytes in EAE. In the 
effector stage, astrocytes contribute to the development of EAE by producing leukocyte-
attracting chemokines, which is negatively regulated by A20. In contrast, in the recovery stage, 
astrocytes are also helpful for EAE recovery by inducing apoptotic elimination of infiltrating T 
cells via FasL (Fig. 28).  
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